<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Med (Lausanne)</journal-id><journal-id journal-id-type="iso-abbrev">Front Med (Lausanne)</journal-id><journal-id journal-id-type="publisher-id">Front. Med.</journal-id><journal-title-group><journal-title>Frontiers in Medicine</journal-title></journal-title-group><issn pub-type="epub">2296-858X</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6224342</article-id><article-id pub-id-type="doi">10.3389/fmed.2018.00296</article-id><article-categories><subj-group subj-group-type="heading"><subject>Medicine</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Diagnosis of Autoimmune Blistering Diseases</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Witte</surname><given-names>Mareike</given-names></name><xref ref-type="corresp" rid="c001"><sup>*</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/587061/overview"/></contrib><contrib contrib-type="author"><name><surname>Zillikens</surname><given-names>Detlef</given-names></name><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/467981/overview"/></contrib><contrib contrib-type="author"><name><surname>Schmidt</surname><given-names>Enno</given-names></name><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/373973/overview"/></contrib></contrib-group><aff><institution>Department of Dermatology, University of L&#x000fc;beck</institution>, <addr-line>L&#x000fc;beck</addr-line>, <country>Germany</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Philippe Musette, Centre Hospitalier Universitaire (CHU) de Rouen, France</p></fn><fn fn-type="edited-by"><p>Reviewed by: Takashi Hashimoto, Osaka University, Japan; Irina Khamaganova, Pirogov Russian National Research Medical University, Russia</p></fn><corresp id="c001">*Correspondence: Mareike Witte <email>mareike.witte@uksh.de</email></corresp><fn fn-type="other" id="fn001"><p>This article was submitted to Dermatology, a section of the journal Frontiers in Medicine</p></fn></author-notes><pub-date pub-type="epub"><day>02</day><month>11</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>5</volume><elocation-id>296</elocation-id><history><date date-type="received"><day>11</day><month>7</month><year>2018</year></date><date date-type="accepted"><day>05</day><month>10</month><year>2018</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2018 Witte, Zillikens and Schmidt.</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Witte, Zillikens and Schmidt</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>Autoimmune skin blistering diseases (AIBD) are characterized by autoantibodies that are directed against structural proteins in the skin and adjacent mucous membranes. Some clinical signs are typical for a specific AIBD, however, correct diagnosis requires the detection of tissue-bound or circulating autoantibodies. The gold standard for diagnosis of AIBD is the detection of autoantibodies or complement component 3 by direct immunofluorescence (DIF) microscopy of a perilesional biopsy. Circulating antibodies can be detected via indirect immunofluorescence (IIF) microscopy of different tissue substrates including human skin, monkey esophagus, and more recently, recombinant forms of the different target antigens. Latter are also employed in various commercial ELISA systems and by immunoblotting in in-house assays available in specialized laboratories. ELISA systems are also particularly valuable for monitoring of the disease activity during the disease course which can be helpful for treatment decisions. Exact diagnosis is essential for both treatment and prognosis, since some AIBD are associated with malign tumors such as paraneoplastic pemphigus and anti-laminin 332 mucous membrane pemphigoid. This review presents clinical and immunopathological features of AIBD for the state-of the art diagnosis of these disorders.</p></abstract><kwd-group><kwd>autoantibody</kwd><kwd>biochip</kwd><kwd>immunofluorescence</kwd><kwd>ELISA</kwd><kwd>pemphigus</kwd><kwd>pemphigoid</kwd><kwd>epidermolysis bullosa acquisita</kwd><kwd>dermatitis herpetiformis</kwd></kwd-group><counts><fig-count count="8"/><table-count count="0"/><equation-count count="0"/><ref-count count="162"/><page-count count="14"/><word-count count="10264"/></counts></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Autoimmune skin blistering diseases (AIBD) are a diverse group of dermatoses that are characterized by autoantibodies binding to antigens in the skin and mucous membranes. They can be subdivided into pemphigoid diseases (PD), with subepidermal split formation and autoantibody binding to structural components of the dermal-epidermal junction (DEJ), and pemphigus, with autoantibodies directed against desmosomal proteins that connect neighboring keratinocytes (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>). A special type of AIBD is dermatitis herpetiformis, with autoantibodies directed against the tissue and epidermal transglutaminase. In this review, we will provide a comprehensive overview about the clinical features and current diagnosis of AIBD extending and updating previous work (<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B4" ref-type="bibr">4</xref>).</p></sec><sec id="s2"><title>Epidemiology</title><p>Bullous pemphigoid (BP) is the most frequent AIBD in Central Europe. Its incidence reaches around 20/million/year. BP is followed by mucous membrane pemphigoid (MMP) and pemphigoid gestationis, with incidences of 2/million/year, respectively (<xref rid="B5" ref-type="bibr">5</xref>&#x02013;<xref rid="B8" ref-type="bibr">8</xref>). Higher incidences of BP have been reported in Great Britain (<xref rid="B9" ref-type="bibr">9</xref>). In contrast to other autoimmune diseases, the incidence of BP is increasing with age. Regarding this matter, its annual incidence in people older than 80 years reaches 150&#x02013;180/million/year (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B6" ref-type="bibr">6</xref>). Like other autoimmune diseases, the incidence of BP is constantly increasing and has nearly doubled in the last decade (<xref rid="B7" ref-type="bibr">7</xref>&#x02013;<xref rid="B11" ref-type="bibr">11</xref>). This is partly due to the rising life expectancy of the general population, increasing awareness, and enhanced diagnostic tests. Further, the close association between BP and neurological diseases [reviewed in (<xref rid="B12" ref-type="bibr">12</xref>)], whose incidences are also rising, may contribute to the increased occurrence of BP. This rise in BP incidence is reflected by hospitalization numbers of BP patients that increased by 26% for a primary diagnosis and by 62% for a secondary diagnosis to 3,260/million inpatients between 2002 and 2012 in the USA (<xref rid="B13" ref-type="bibr">13</xref>).</p><p>In pemphigus, the incidence depends on the geographical region. In Central Europe and the United States, its incidence is estimated between 1 and 7 new patients/million/year (<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B14" ref-type="bibr">14</xref>). Generally, PV is more common than pemphigus foliaceus (PF), with ratios ranging from 4:1 to 9:1 (<xref rid="B15" ref-type="bibr">15</xref>). In Tunisia and Brazil, endemic forms of PF with much higher incidences are present (<xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B17" ref-type="bibr">17</xref>).</p><p>The prevalence of AIBD in Germany have recently been calculated based on the ICD-coding-based dataset of the country's largest health insurance. The study revealed about 40,000 AIBD patients including 21,000 patients with BP, 7,700 with PV, and around 2,000 with MMP (<xref rid="B18" ref-type="bibr">18</xref>).</p></sec><sec id="s3"><title>Historical background</title><p>The term pemphigus was first used by Hippocrates in 460&#x02013;370 B.C. (<xref rid="B19" ref-type="bibr">19</xref>). However, the differentiation between pemphigus and BP was first made by Walter Lever in 1953 based on lesional histopathology (<xref rid="B20" ref-type="bibr">20</xref>). In 1964 and 1967, detection of autoantibodies in serum and skin were reported for pemphigus and BP (<xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B22" ref-type="bibr">22</xref>), providing milestones for the diagnosis of AIBD. Diagnosis of the different AIBD entities became subsequently possible by the molecular identification of target antigens (<xref rid="B23" ref-type="bibr">23</xref>). In parallel it became clear that the autoantibodies used for the diagnosis of AIBDs may be directly pathogenic (<xref rid="B24" ref-type="bibr">24</xref>&#x02013;<xref rid="B29" ref-type="bibr">29</xref>), reviewed in (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B30" ref-type="bibr">30</xref>&#x02013;<xref rid="B34" ref-type="bibr">34</xref>).</p></sec><sec id="s4"><title>Direct immunofluorescence microscopy</title><p>The diagnosis of AIBDs is based on the combination of the clinical presentation and detection of tissue-bound and/or circulating autoantibodies. Tissue-bound autoantibodies can be detected via direct immunofluorescence (DIF) microscopy, which is the diagnostic gold standard for AIBD. For DIF microscopy, cryosections of perilesional biopsies are required and need to be snap frozen and stored at &#x02212;20&#x000b0;C or conserved in isotonic NaCl or modified Michels medium until processed (<xref rid="B35" ref-type="bibr">35</xref>, <xref rid="B36" ref-type="bibr">36</xref>).</p><p>DIF microscopy only provides limited information about the target antigen(s), however the diagnosis can be narrowed down according to the immunoglobulin subclass and binding pattern. In pemphigus, DIF microscopy reveals intercellular binding of IgG and/or C3 within the epidermis and/or epithelium. In pemphigoid diseases, a linear deposition of IgG and/or C3 at the DEJ can be observed (Figures <xref ref-type="fig" rid="F1">1</xref>, <xref ref-type="fig" rid="F2">2</xref>). Linear staining at the DEJ can further be differentiated into n-serrated and u-serrated patterns. In an n-serration pattern, arches are closed at the top (Figure <xref ref-type="fig" rid="F3">3</xref> left) and in a u-serrated staining pattern, arches are closed at the bottom appearing like &#x0201c;growing grass&#x0201d; (Figure <xref ref-type="fig" rid="F3">3</xref> right). While u-serration is unique for antibody binding to type VII collagen and can been seen in epidermolysis bullosa acquisita (EBA), n-serration is found in all other pemphigoid diseases (<xref rid="B37" ref-type="bibr">37</xref>&#x02013;<xref rid="B39" ref-type="bibr">39</xref>). Serration pattern analysis can be performed in any routine immunofluorescence (IF) laboratory and is best performed in 6 &#x003bc;m sections and 400- or 600-fold magnification without oil (<xref rid="B38" ref-type="bibr">38</xref>, <xref rid="B39" ref-type="bibr">39</xref>). IF pictures for training of serration pattern analysis are freely available (<ext-link ext-link-type="uri" xlink:href="http://www.nversusu.umcg.nl">www.nversusu.umcg.nl</ext-link>).</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Differential diagnosis of autoimmune skin blistering diseases based on direct immunofluorescence (DIF) microscopy of a perilesional biopsy. BP, bullous pemphigoid; EBA, epidermolysis bullosa acquisita; MMP, mucous membrane pemphigoid; PF, pemphigus foliaceus; PNP, paraneoplastic pemphigus; PV, pemphigus vulgaris; *may be combined with linear deposition.</p></caption><graphic xlink:href="fmed-05-00296-g0001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><p>Clinical and immunopathological characteristics in bullous pemphigoid (BP, <bold>left</bold>), pemphigus vulgaris (PV, <bold>middle</bold>), and epidermolysis bullosa acquisita (EBA, <bold>right</bold>).</p></caption><graphic xlink:href="fmed-05-00296-g0002"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><p>n-serrated <bold>(left)</bold> and u-serrated pattern <bold>(right)</bold> of basement membrane zone staining in pemphigoid diseases detected by direct immunofluorescence microscopy. While an u-serrated pattern is exclusively seen in epidermolysis bullosa acquisita, an n-serrated pattern can be detected in all other pemphigoid diseases.</p></caption><graphic xlink:href="fmed-05-00296-g0003"/></fig><p>In dermatitis herpetiformis, DIF microscopy reveals granular deposition of IgA at the dermal papillae and along the DEJ. An automated staining for DIF microscopy sections has recently been developed and revealed more intensive IF staining and reduced background compared to the manual procedure due to continuous movement and overhead incubation (<xref rid="B40" ref-type="bibr">40</xref>). A flowchart navigating through differential diagnoses using DIF microscopy is shown in Figure <xref ref-type="fig" rid="F1">1</xref>. For further differentiation of the target antigen(s) serological analyses is required.</p></sec><sec id="s5"><title>Indirect immunofluorescence microscopy using tissue substrates</title><p>Several tissues can be employed by indirect IF (IIF) microscopy to screen for serum autoantibodies in AIBD including monkey, rabbit, guinea pig, and human esophagus (for pemphigus and pemphigoid diseases), monkey and rat bladder (for paraneoplastic pemphigus), and amnion epithelium (for BP and PV). In one study, monkey esophagus was the most sensitive substrate for pemphigus; another study showed that monkey esophagus is more sensitive for PV and human esophagus is more sensitive for PF (<xref rid="B41" ref-type="bibr">41</xref>&#x02013;<xref rid="B44" ref-type="bibr">44</xref>). The most frequently used substrates are monkey esophagus and human split skin. On monkey esophagus, autoantibodies in pemphigus reveal intercellular labeling of the epithelium and linear staining of the DEJ in pemphigoid diseases (Figure <xref ref-type="fig" rid="F2">2</xref>). Sensitivities of 90% and 73.2% have been reported for pemphigus and BP, respectively (<xref rid="B41" ref-type="bibr">41</xref>, <xref rid="B43" ref-type="bibr">43</xref>). In dermatitis herpetiformis, IgA binds to the endomysium. The tissue substrate with the highest sensitivity for autoantibodies in pemphigoid diseases is 1M NaCl split human skin. Here, antibodies bind either to the epidermal (&#x0201c;roof&#x0201d;) or dermal (&#x0201c;floor&#x0201d;) side of the artificial blister (Figure <xref ref-type="fig" rid="F2">2</xref>, left and right panel, respectively). &#x0201c;Floor&#x0201d;-binding antibodies can be detected in EBA, anti-p200/laminin &#x003b3;1 pemphigoid, and anti-laminin 332 MMP. &#x0201c;Roof&#x0201d;-binding antibodies target BP180 and BP230 and are observed in BP, linear IgA-disease, pemphigoid gestationis, and anti-BP180-type mucous membrane pemphigoid. Sensitivities for BP range between 73 and 84% (<xref rid="B41" ref-type="bibr">41</xref>, <xref rid="B45" ref-type="bibr">45</xref>).</p><p>The most sensitive substrates for the detection of anti-plakin reactivity are monkey and rat bladder epithelium. In pemphigoid gestationis, the complement fixation test detects complement-fixing IgG on human salt-split skin. For definite diagnosis of most AIBD refined analysis of serum autoantibodies can be performed, employing recombinant or cell-derived antigens. A flowchart depicting the serological diagnosis of autoimmune blistering diseases is shown in Figure <xref ref-type="fig" rid="F4">4</xref>.</p><fig id="F4" position="float"><label>Figure 4</label><caption><p>Differential diagnosis of autoimmune skin blistering diseases based on the serological detection of autoantibodies. Dsc, desmocollin; Dsg, desmoglein; EBA, epidermolysis bullosa acquisita; * commercial assays are available; ** available by the end of 2018.</p></caption><graphic xlink:href="fmed-05-00296-g0004"/></fig></sec><sec id="s6"><title>Target antigen-specific analysis of serum autoantibodies</title><p>For the identification of the target antigen, three main systems have been described: (i) Enzyme-linked immunosorbent assay (ELISA), (ii) IIF microscopy, and (iii) immunoblot/immunoprecipitation.</p><list list-type="roman-lower"><list-item><p>ELISA systems allow the identification and quantification of autoantibodies against specific autoantigens. They are applied for both diagnosis and monitoring of the activity of the disease during the disease process (<xref rid="B46" ref-type="bibr">46</xref>). For pemphigoid diseases, commercial ELISA systems include BP180 NC16A, BP230, and type VII collagen, which employ recombinant protein, respectively (MBL, Euroimmun) (<xref rid="B47" ref-type="bibr">47</xref>&#x02013;<xref rid="B52" ref-type="bibr">52</xref>). The sensitivity of the BP180 NC16A ELISA ranges between 84 and 89% in BP (<xref rid="B47" ref-type="bibr">47</xref>, <xref rid="B49" ref-type="bibr">49</xref>, <xref rid="B53" ref-type="bibr">53</xref>) and between 96 and 97% in pemphigoid gestations (<xref rid="B54" ref-type="bibr">54</xref>, <xref rid="B55" ref-type="bibr">55</xref>). The sensitivity in BP can be increased by the additional use of the BP230 ELISA by about 5% (<xref rid="B52" ref-type="bibr">52</xref>, <xref rid="B56" ref-type="bibr">56</xref>, <xref rid="B57" ref-type="bibr">57</xref>). For pemphigus, ELISA systems employ the ectodomains of Dsg1 and Dsg3 recombinantly expressed in HEK293 cells (Euroimmun) or baculovirus (MBL, Nagoya, Japan) (<xref rid="B46" ref-type="bibr">46</xref>, <xref rid="B58" ref-type="bibr">58</xref>, <xref rid="B59" ref-type="bibr">59</xref>). For paraneoplastic pemphigus, an ELISA system for autoantibodies against envoplakin has been developed (Euroimmun) (<xref rid="B60" ref-type="bibr">60</xref>). For dermatitis herpetiformis, ELISA systems for the detection of coeliac-specific gliadin IgG and IgA autoantibodies as well as anti-transglutaminase 2 and 3-antibodies are available (<xref rid="B61" ref-type="bibr">61</xref>). ELISA systems that are less standardized and only available in specialized laboratories include desmocollin (<xref rid="B62" ref-type="bibr">62</xref>, <xref rid="B63" ref-type="bibr">63</xref>), laminin &#x003b3;1 (<xref rid="B64" ref-type="bibr">64</xref>, <xref rid="B65" ref-type="bibr">65</xref>), the ectodomain of BP180 (<xref rid="B66" ref-type="bibr">66</xref>), full-length BP180 (<xref rid="B67" ref-type="bibr">67</xref>), laminin 332 (<xref rid="B68" ref-type="bibr">68</xref>, <xref rid="B69" ref-type="bibr">69</xref>) and BP180 NC16A-IgE-ELISA (<xref rid="B70" ref-type="bibr">70</xref>&#x02013;<xref rid="B72" ref-type="bibr">72</xref>) as well as other forms of BP180 (<xref rid="B73" ref-type="bibr">73</xref>, <xref rid="B74" ref-type="bibr">74</xref>).</p></list-item></list><p>In addition, two multivariant ELISA systems compiled of the individual assays include recombinant Dsg 1 and 3, BP180 NC16A, BP230, type VII collagen, and only in one system, envoplakin, are widely available (<xref rid="B75" ref-type="bibr">75</xref>, <xref rid="B76" ref-type="bibr">76</xref>).</p><list list-type="simple"><list-item><p>(ii) IIF-based assays employing recombinant forms of the target antigens are available as multivariant assays and thus, offer a single-step method for the diagnosis of AIBDs. These assays are based on the BIOCHIP&#x000ae; mosaic technology using normally-sized laboratory slides with 5&#x02013;10 incubation fields. The serum sample is loaded onto an incubation field, consisting of several miniature biochips coated with different substrates (e.g., monkey esophagus, salt-split skin, recombinant BP180 NC16A or HEK293 cells recombinantly expressing Dsg1, Dsg3, or BP230). We have shown that the sensitivity and specificity of BIOCHIP&#x000ae; mosaic analysis is comparable to that of ELISA systems regarding AIBDs (<xref rid="B77" ref-type="bibr">77</xref>). Meanwhile, this technology has been applied in different routine laboratories worldwide (<xref rid="B78" ref-type="bibr">78</xref>&#x02013; <xref rid="B80" ref-type="bibr">80</xref>). More recently, a mosaic comprising 4 biochips coated with recombinant BP180 NC16A, HEK cells expressing BP230, salt-split skin and monkey esophagus, respectively, showed a sensitivity of 100% when testing with pemphigoid gestationis sera (<xref rid="B79" ref-type="bibr">79</xref>). A BIOCHIP&#x000ae; mosaic including the immunodominant NC1 domain of type VII collagen yielded sensitivities of 92 and 100% (<xref rid="B50" ref-type="bibr">50</xref>, <xref rid="B81" ref-type="bibr">81</xref>), indicating that BIOCHIP&#x000ae; technology is a valuable tool in the routine diagnosis of pemphigoid gestationis and EBA. As for desmocollins, anti-desmocollin IgG and/or IgA reactivity was only found in about 3% of around 400 pemphigus sera, using a BIOCHIP&#x000ae; mosaic containing recombinant forms of desmocollin 1, &#x02212;2, and &#x02212;3 (<xref rid="B82" ref-type="bibr">82</xref>). Therefore, according to the guidelines of the German Dermatological Society, the analysis for anti-desmocollin reactivity is only recommended in patients with IgA pemphigus, pemphigus vegetans, atypical pemphigus, and the rare patients with pemphigus vulgaris/foliaceus without anti-Dsg reactivity (<xref rid="B36" ref-type="bibr">36</xref>). Most recently, a BIOCHIP&#x000ae; mosaic was developed containing recombinant chains of laminin 332 for the diagnosis of anti-laminin 332-pemphigoid (<xref rid="B83" ref-type="bibr">83</xref>) (Figure <xref ref-type="fig" rid="F5">5</xref>). This BIOCHIP&#x000ae; mosaic yields sensitivities between 75 and 85% with a specificity of nearly 100% (<xref rid="B83" ref-type="bibr">83</xref>).</p></list-item><list-item><p>(iii) Immunoblotting and immunoprecipitation are performed using recombinant proteins or extracts of dermis, epidermis, bovine gingiva, amnion membrane or cultured keratinocytes (<xref rid="B80" ref-type="bibr">80</xref>&#x02013;<xref rid="B86" ref-type="bibr">86</xref>). These systems are part of the diagnostic algorithm for AIBD in some laboratories. They can be used for the detection of anti-p200 autoantibodies (Figure <xref ref-type="fig" rid="F6">6</xref>), anti-laminin &#x003b3;1 autoantibodies, antibodies against C-terminal stretches of BP180, and the soluble ectodomain of BP180 (LAD-1; Figure <xref ref-type="fig" rid="F7">7</xref>), as well as autoantibodies against cell-derived forms of envoplakin, periplakin, desmoplakin, BP180, BP230, &#x003b1;4&#x003b2;6-integrin, laminin 332, and type VII collagen (Figure <xref ref-type="fig" rid="F6">6</xref>) (<xref rid="B87" ref-type="bibr">87</xref>). Latter test systems are, however, only available in specialized laboratories including the autoimmune laboratory of the Department of Dermatology, L&#x000fc;beck, Germany (<xref rid="B88" ref-type="bibr">88</xref>). The laboratory has been accredited by Deutsche Akkreditierungsstelle (DAkkS D-ML-13069-06-00) and is also involved in the development of novel assay systems (<ext-link ext-link-type="uri" xlink:href="http://www.uksh.de/dermatologie-luebeck/Infos+f&#x000fc;r+&#x000c4;rzte+und+Einsender/Autoimmunlabor.html">www.uksh.de/dermatologie-luebeck/Infos+f&#x000fc;r+&#x000c4;rzte+und+Einsender/Autoimmunlabor.html</ext-link>). The main diagnostic algorithm of our laboratory is shown in Figure <xref ref-type="fig" rid="F4">4</xref> and further detailed in Schmidt et al. (<xref rid="B3" ref-type="bibr">3</xref>).</p></list-item></list><fig id="F5" position="float"><label>Figure 5</label><caption><p>Anti-laminin 332 BIOCHIP&#x000ae; mosaic. The mosaic contains HEK293 cells expressing the recombinant laminin 332 heterotrimer (Trim; upper left and middle left), the recombinant &#x003b3;2- t &#x003b2;3-, and &#x003b1;3-chains of laminin 332 as well as negative control, cells transfected with the empty vector. Here, antibody binding is seen with the heterotrimer and the &#x003b2;3- and &#x003b1;3-chains in a patient with anti-laminin 332 mucous membrane pemphigoid.</p></caption><graphic xlink:href="fmed-05-00296-g0005"/></fig><fig id="F6" position="float"><label>Figure 6</label><caption><p>Detection of serum autoantibodies against the p200 protein and type VII collagen by Western blotting with extract of human dermis. Sera from a patient with anti-p200/laminin &#x003b3;1 pemphigoid and epidermolysis bullosa acquisita (EBA), respectively, showed IgG4 reactivity against the p200 antigen <bold>(lower arrow)</bold> and type VII collagen <bold>(upper arrow)</bold>. In the right lane, a normal human serum (NHS) was applied.</p></caption><graphic xlink:href="fmed-05-00296-g0006"/></fig><fig id="F7" position="float"><label>Figure 7</label><caption><p>Detection of IgG and IgA autoantibodies against LAD-1 by Western blotting with the concentrated conditioned medium of cultured human keratinocytes. Sera from patients with bullous pemphigoid (BP), mucous membrane pemphigoid (MMP), both without BP180 NC16A IgG by ELISA, showed IgG reactivity with the soluble ectodomain of BP180 (LAD-1; <bold>left</bold>, arrow). In serum of a patient with linear IgA disease, IgA antibodies against LAD-1 were present <bold>(right)</bold>. NHS, normal human serum.</p></caption><graphic xlink:href="fmed-05-00296-g0007"/></fig></sec><sec id="s7"><title>Diagnostically relevant clinical and immunopathological characteristics of major AIBD</title><sec><title>Pemphigus vulgaris and pemphigus foliaceus</title><p>Pemphigus can be divided in two major clinical subtypes, PV and PF. Autoantibodies in pemphigus are directed against epidermal desmosomes, mainly desmoglein (Dsg) 1 and 3. A common clinical finding is a positive Nikolsky sign. Here, mechanical friction of perilesional skin results in exfoliation of the outermost skin layer. The Nikolsky sign moderately sensitive, but highly specific in the diagnosis of pemphigus (<xref rid="B89" ref-type="bibr">89</xref>). PF is clinically characterized by flaccid, superficial erosions preferentially in seborrheic areas. The erosions are usually covered by scaling, which is due to the detachment of the superficial layers of the epidermis (<xref rid="B90" ref-type="bibr">90</xref>). In PF, mucous membranes are completely spared (<xref rid="B3" ref-type="bibr">3</xref>). Autoantibodies in PF are directed against Dsg1 and can be detected by ELISA or IIF microscopy (<xref rid="B46" ref-type="bibr">46</xref>, <xref rid="B88" ref-type="bibr">88</xref>, <xref rid="B91" ref-type="bibr">91</xref>) (Figure <xref ref-type="fig" rid="F4">4</xref>). In nearly all PF patients, anti-Dsg1 serum levels closely correlate with disease activity (<xref rid="B46" ref-type="bibr">46</xref>).</p><p>In contrast to PF, patients with PV always suffer from mucous membrane lesions (Figure <xref ref-type="fig" rid="F2">2</xref> middle). These are accompanied to a variable extent with blisters and/or erosions of the skin. Autoantibodies in PV are directed against Dsg 3 (<xref rid="B92" ref-type="bibr">92</xref>). When in addition to mucosal involvement, lesions are also present on the skin, patients with PV also have autoantibodies against Dsg1 (<xref rid="B1" ref-type="bibr">1</xref>). According to the extent of affected skin, three types of PV can be distinguished: (i) the mucosal-dominant type with limited cutaneous involvement (Dsg 3-autoantibodies are predominant), (ii) the mucocutaneous type with both mucosal and cutaneous involvement (Dsg3- and Dsg1-autoantibodies are equally predominant) and the cutaneous type with predominant anti-Dsg1 and pathogenically weak anti-Dsg3 autoantibodies (<xref rid="B1" ref-type="bibr">1</xref>). Alike Dsg1-specific autoantibodies, anti-Dsg3-autoantibodies can be detected by ELISA (<xref rid="B46" ref-type="bibr">46</xref>). Both Dsg1- and 3-autoantibody levels correlate with the disease activity and can therefore be used as disease activity marker (<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B46" ref-type="bibr">46</xref>).</p></sec><sec><title>Paraneoplastic pemphigus</title><p>Paraneoplastic pemphigus (PNP) is an AIBD that is characterized by its association with malignant (or rarely benign) neoplasms. The most frequently associated neoplasms are B-cell lymphoma, Castleman disease, chronic lymphocytic leukemia, thymoma, and Waldenstrom macroglobulinemia (<xref rid="B84" ref-type="bibr">84</xref>, <xref rid="B93" ref-type="bibr">93</xref>, <xref rid="B94" ref-type="bibr">94</xref>). The clinical phenotype is diverse. First, PNP mainly affects the oral mucosa with other mucous membranes less frequently involved (<xref rid="B95" ref-type="bibr">95</xref>&#x02013;<xref rid="B97" ref-type="bibr">97</xref>). Cutaneous lesions may arise on any part of the skin and may include: (i) pemphigus-like lesions with flaccid blisters, erosions, erythema and crusts; (ii) BP-like lesions such as urticarial lesions and tense blisters (<xref rid="B96" ref-type="bibr">96</xref>); (iii) erythema multiforme-like lesions and (iv) lichen planus-like lesions presenting as flat scaly papules and intense mucous membrane involvement (<xref rid="B95" ref-type="bibr">95</xref>). Furthermore, pulmonary destruction leading to bronchiolitis obliterans was noticed in many PNP-patients (<xref rid="B98" ref-type="bibr">98</xref>).</p><p>Apart from Dsg3, the autoantibodies may be directed against plakins such as BP230, periplakin, envoplakin, desmoplakin 1 and 2, and plectin (<xref rid="B84" ref-type="bibr">84</xref>). More recently, antibodies against desmocollins, &#x003b1;2 macroglobulin-like 1, and epiplakin have been described (<xref rid="B62" ref-type="bibr">62</xref>, <xref rid="B99" ref-type="bibr">99</xref>, <xref rid="B100" ref-type="bibr">100</xref>) (Figure <xref ref-type="fig" rid="F4">4</xref>). Antibodies against envoplakin and periplakin are most frequent (<xref rid="B60" ref-type="bibr">60</xref>, <xref rid="B101" ref-type="bibr">101</xref>, <xref rid="B102" ref-type="bibr">102</xref>). They can be detected via Western blotting or immunoprecipitation of extracts from keratinocytes (<xref rid="B84" ref-type="bibr">84</xref>), and, more conveniently, by a commercial ELISA employing the recombinant N-terminus of envoplakin (<xref rid="B60" ref-type="bibr">60</xref>).</p></sec><sec><title>Bullous pemphigoid</title><p>In BP, autoantibodies are directed against a 180 kDa-sized (BP180/BPAG2/XVII collagen) and/or a 230 kDa-sized (BP230/BPAG1) antigen, which are essential for dermal-epidermal adhesion (<xref rid="B103" ref-type="bibr">103</xref>) (Figure <xref ref-type="fig" rid="F2">2</xref> left). The disease is mainly diagnosed in people aged between 75 and 80 years (<xref rid="B18" ref-type="bibr">18</xref>). It rarely occurs in people under the age of 50 years with few children described with BP (<xref rid="B104" ref-type="bibr">104</xref>). In nearly all patients with BP, intense pruritus is present (<xref rid="B105" ref-type="bibr">105</xref>). Classically, BP presents with tense blisters and erosions. In contrast to pemphigus, the Nikolsky sign is negative. Alternatively or additionally, urticarial and erythematous non-bullous lesions are present (<xref rid="B106" ref-type="bibr">106</xref>). In fact, about 20% of patients present with non-bullous variants with excoriations, erythematous, or urticarial lesions (<xref rid="B107" ref-type="bibr">107</xref>). Non-bullous lesions also usually develop during a prodromal stage that may last for several months. Mucosal lesions, which occur in 15&#x02013;20% of the BP patients, are associated with high disease severity and with absence of anti-BP230 antibodies (<xref rid="B108" ref-type="bibr">108</xref>).</p><p>BP180 is a collagen-type transmembrane glycoprotein of about 1,500 amino acids. It is a heterotrimer, consisting of a globular intracellular domain, a short transmembranous segment, and an extracellular C-terminal domain composed of 15 collagen repeats that are separated by 16 noncollagenous (NC) subdomains (<xref rid="B109" ref-type="bibr">109</xref>). The C-terminal domain forms a loop structure as it goes through the lamina lucida, spans the lamina densa, and then bends back into the lamina lucida (<xref rid="B110" ref-type="bibr">110</xref>). The 16th of the extracellular non-collagenous subdomains, NC16A, is the immunodominant region in BP (<xref rid="B111" ref-type="bibr">111</xref>). It is used in two ELISA systems (<xref rid="B47" ref-type="bibr">47</xref>, <xref rid="B48" ref-type="bibr">48</xref>) (Figure <xref ref-type="fig" rid="F4">4</xref>), which on the one hand provide a sensitive and specific diagnostic tool for the routine diagnosis of BP and on the other hand are used to monitor the serum levels of anti-BP180 NC16A antibodies during the course of the disease (<xref rid="B112" ref-type="bibr">112</xref>). Alternatively, an IIF test using recombinant NC16A is widely available (<xref rid="B77" ref-type="bibr">77</xref>) (Figure <xref ref-type="fig" rid="F4">4</xref>). In most of the BP patients, autoantibodies are also directed against BP180-epitopes outside the NC16A-domain (<xref rid="B113" ref-type="bibr">113</xref>). In the 10&#x02013;15% of BP patients with no reactivity against NC16A, testing for those antibodies is recommended; however, no commercial assay is available so far. In addition to several recombinant fragments of the C-terminal part of BP180, the cell-derived 120 kDa shed ectodomain present in the conditioned concentrated medium of cultures keratinocytes can be applied by immunoblotting for the detection of non-NC16A-reactive sera.</p><p>The major immunoglobulin class in BP is IgG. However, it has been shown that some patients also develop anti-BP180 IgA and IgE autoantibodies (<xref rid="B114" ref-type="bibr">114</xref>). In fact, most of the BP sera contain both IgG and IgA autoantibodies to BP180 (<xref rid="B114" ref-type="bibr">114</xref>, <xref rid="B115" ref-type="bibr">115</xref>). Anti-BP180 IgE antibodies can be detected in 30&#x02013;95% of the BP patients, and their detection corresponds to a high disease severity (<xref rid="B70" ref-type="bibr">70</xref>, <xref rid="B116" ref-type="bibr">116</xref>).</p><p>BP230 is an intracellular component of the hemidesmosomal anchoring complex. It is a member of the plakin family. Anti-BP230 IgG can be detected in the serum of 40&#x02013;60% of the BP patients. Like for BP180, commercial ELISA systems are available for the detection of anti-BP230 antibodies, which can be used for the diagnosis of BP (<xref rid="B49" ref-type="bibr">49</xref>, <xref rid="B52" ref-type="bibr">52</xref>) (Figure <xref ref-type="fig" rid="F4">4</xref>). 80% of the anti-BP230 autoantibodies found in the sera of BP patients most frequently target the globular C-terminal domain of BP230 that interacts with keratin filaments (<xref rid="B117" ref-type="bibr">117</xref>, <xref rid="B118" ref-type="bibr">118</xref>). However, it remains unclear whether anti-BP230 antibodies are directly pathogenic (<xref rid="B119" ref-type="bibr">119</xref>). Also, unlike anti-BP180, serum levels of anti-BP230-antibodies do not correlate with the disease activity in BP patients (<xref rid="B120" ref-type="bibr">120</xref>). However, the detection of anti-BP230 autoantibodies remains a useful tool for the diagnosis of BP. Regarding this matter, the combined use of the BP180 and BP230 ELISA system provides a sensitivity of around 90% for the detection of circulating autoantibodies (<xref rid="B52" ref-type="bibr">52</xref>, <xref rid="B56" ref-type="bibr">56</xref>, <xref rid="B57" ref-type="bibr">57</xref>).</p></sec><sec><title>Pemphigoid gestationis</title><p>Pemphigoid gestationis (previously called herpes gestationis) is a dermatosis of pregnancy. It usually occurs during the third trimenon and less commonly, in the second trimenon or post partal period (<xref rid="B121" ref-type="bibr">121</xref>, <xref rid="B122" ref-type="bibr">122</xref>). In contrast to BP, blisters are infrequent and usually small with predominating urticarial erythema frequently initiating around the umbilicus. Pemphigoid gestationis tends to recur in subsequent pregnancies, appearing earlier and with a more severe course. Serum autoantibodies to BP180 NC16A can be detected in &#x0003e;95% of the patients by ELISA, having a sensitivity of 97% (Figure <xref ref-type="fig" rid="F4">4</xref>) (<xref rid="B47" ref-type="bibr">47</xref>, <xref rid="B55" ref-type="bibr">55</xref>). Recently, Sadik et al. detected NC16A reactivity in all of a large cohort of 65 pemphigoid gestationis sera using an IIF test based on the Biochip&#x000ae; mosaic technology (<xref rid="B123" ref-type="bibr">123</xref>). The main IgG subclasses are IgG1 and IgG3, explaining their high potential for the fixation of complement (<xref rid="B124" ref-type="bibr">124</xref>), a feature that is exploited by the IIF complement binding test that visualizes complement-binding anti-basement membrane antibodies (Figure <xref ref-type="fig" rid="F4">4</xref>). Anti-BP230 reactivity is found in only 10% of sera (<xref rid="B123" ref-type="bibr">123</xref>).</p></sec><sec><title>Mucous membrane pemphigoid</title><p>MMP is defined as pemphigoid disease with predominant involvement of mucous membranes (<xref rid="B125" ref-type="bibr">125</xref>). It usually affects the mucous membranes of the mouth, eyes and genitals. Complications of the disease are conjunctival involvement and blindness, which may cause serious morbidity (Figure <xref ref-type="fig" rid="F8">8</xref>) (<xref rid="B126" ref-type="bibr">126</xref>, <xref rid="B127" ref-type="bibr">127</xref>). Diagnosis is made by DIF microscopy of a perilesional biopsy, showing linear deposition of IgG and/or IgA and/or C3 along the DEJ (Figure <xref ref-type="fig" rid="F1">1</xref>) (<xref rid="B126" ref-type="bibr">126</xref>). In IIF microscopy, autoantibodies can only be detected in 50% of the MMP patients. Therefore, immunoprecipitation, Western blotting, and ELISA systems that employ cell-derived and recombinant proteins are essential diagnostic tests for MMP (Figure <xref ref-type="fig" rid="F4">4</xref>) (<xref rid="B126" ref-type="bibr">126</xref>). The main target antigen in MMP is BP180. However, in contrast to BP, the NC16A domain is only targeted in around 50%. More commonly, the autoantibodies target C-terminal epitopes of BP180 such as LAD-1, the soluble ectodomain of BP180 (<xref rid="B128" ref-type="bibr">128</xref>, <xref rid="B129" ref-type="bibr">129</xref>). Those autoantibodies can be detected by Western blotting, using the respective recombinant fragments of the C-terminus of BP180. Both anti-BP180 IgG and IgA are predominant in anti-BP180-type MMP. Therefore, it is necessary to test for both isotypes (Figure <xref ref-type="fig" rid="F4">4</xref>) (<xref rid="B128" ref-type="bibr">128</xref>). Further antigens in MMP are laminin 332 as well as &#x003b1;6 and &#x003b2;4 integrin. Anti-laminin 332 antibodies can be detected in around 25% of the MMP-patients (<xref rid="B128" ref-type="bibr">128</xref>, <xref rid="B130" ref-type="bibr">130</xref>). Laminin 332, which was formerly known as epiligrin or laminin 5, is a heterotrimeric protein composed of an &#x003b1;3, &#x003b2;3, and &#x003b3;2 subunit. Anti-laminin 332 autoantibodies typically target the &#x003b1;3 chain (<xref rid="B131" ref-type="bibr">131</xref>). Since the presence of anti-laminin 332 autoantibodies is associated with development of malignancies in 25% (<xref rid="B38" ref-type="bibr">38</xref>, <xref rid="B132" ref-type="bibr">132</xref>, <xref rid="B133" ref-type="bibr">133</xref>), screening for anti-laminin 332 reactivity is strongly recommended in every MMP patient and in case of positivity, a tumor search is mandatory. Unfortunately, no detection system for serum antibodies against laminin 332 is widely available. A sensitive and highly specific assay for serum anti-laminin 332 IgG based on the Biochip&#x000ae; mosaic technology has recently been developed (<xref rid="B83" ref-type="bibr">83</xref>) and will be commercialized later in 2018. Antibodies against &#x003b1;6 and &#x003b2;4 integrin were detected in a few cases of oral and conjunctival MMP, respectively (<xref rid="B134" ref-type="bibr">134</xref>).</p><fig id="F8" position="float"><label>Figure 8</label><caption><p>Clinical findings in mucous membrane pemphigoid affecting the conjunctiva, lips, gingiva, and glans penis.</p></caption><graphic xlink:href="fmed-05-00296-g0008"/></fig></sec><sec><title>Linear IgA disease</title><p>Linear IgA disease (LAD) is characterized by subepidermal blistering and linear deposition of predominantly IgA at the DEJ. The disease is characterized by its heterogenous phenotype that may be similar to other autoimmune skin blistering diseases. Mostly, the patients present with vesiculobullous lesions on the skin and adjacent mucous membranes (<xref rid="B135" ref-type="bibr">135</xref>, <xref rid="B136" ref-type="bibr">136</xref>). Using DIF microscopy of a perilesional biopsy, a linear deposition of IgA autoantibodies along the DEJ can be detected (Figure <xref ref-type="fig" rid="F1">1</xref>). The autoantibodies bind to antigens of different molecular weights, including 97-, 120-, 180-, 200-, 230-, 280-, 285-, and 290-kDa proteins (<xref rid="B137" ref-type="bibr">137</xref>&#x02013;<xref rid="B139" ref-type="bibr">139</xref>). According to the IIF findings, LAD can be divided into the lamina lucida type, where sera react with the epidermal side of salt-split skin and mostly with LAD-1 (<xref rid="B140" ref-type="bibr">140</xref>), and the sublamina densa type, that reveals serum antibodies against the dermal side of salt-split skin recognizing type VII collagen (<xref rid="B138" ref-type="bibr">138</xref>, <xref rid="B141" ref-type="bibr">141</xref>, <xref rid="B142" ref-type="bibr">142</xref>) (Figure <xref ref-type="fig" rid="F4">4</xref>). Interestingly, a recent study showed that type VII collagen is also the most common target antigen in vancomycine-induced LAD (<xref rid="B143" ref-type="bibr">143</xref>). Due to sematic overlap, patients with IgA reactivity against type VII collagen can also be classified as IgA EBA, a view that is supported by a recent consensus of an international expert panel (<xref rid="B144" ref-type="bibr">144</xref>).</p></sec><sec><title>Anti-P200/anti-laminin &#x003b3; 1 pemphigoid</title><p>Anti-p200 pemphigoid is an autoimmune skin blistering disease with antibodies directed against a 200 kDa protein of the DEJ (<xref rid="B145" ref-type="bibr">145</xref>). Since laminin &#x003b3;1 is the target antigen in 90% of the cases, it is also known as anti-laminin &#x003b3;1 pemphigoid (<xref rid="B65" ref-type="bibr">65</xref>). Like LAD, the clinical presentation is heterogeneous and in most of the cases resembles BP and the inflammatory variant of EBA. The lesions heal without scarring or milia formation. Mucous membranes are involved in about 20% of the patients (<xref rid="B146" ref-type="bibr">146</xref>). Palmoplantar involvement seems to be more frequent compared to BP and a high association with psoriasis is seen in Japanese patients with anti-laminin 332 pemphigoid (<xref rid="B146" ref-type="bibr">146</xref>, <xref rid="B147" ref-type="bibr">147</xref>). Antibodies against p200 bind to the floor of the artificial blister of salt-split skin using IIF microscopy (Figure <xref ref-type="fig" rid="F4">4</xref>). They can be detected by Western blotting with extracts of human dermis (Figure <xref ref-type="fig" rid="F6">6</xref>) (<xref rid="B145" ref-type="bibr">145</xref>). However, the preparation of those extracts is challenging and problematic. Therefore, an ELISA system was developed, using the recombinant C-terminus of laminin &#x003b3;1, with a sensitivity of around 70% and a specificity of nearly 99% (<xref rid="B64" ref-type="bibr">64</xref>).</p></sec><sec><title>Epidermolysis bullosa acquisita</title><p>EBA affects skin and, to less extent, mucous membranes and is characterized by autoantibodies against type VII collagen (Figure <xref ref-type="fig" rid="F2">2</xref> right) (<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B148" ref-type="bibr">148</xref>). There are two main clinical forms of EBA (<xref rid="B144" ref-type="bibr">144</xref>, <xref rid="B149" ref-type="bibr">149</xref>, <xref rid="B150" ref-type="bibr">150</xref>). The mechanobullous form represents the classical form of EBA. It is clinically characterized by skin fragility, tense blisters, vesicles, and erosions on non-inflamed skin in trauma-prone sites. Lesions may heal with scarring and milia formation (<xref rid="B149" ref-type="bibr">149</xref>, <xref rid="B151" ref-type="bibr">151</xref>). In about two thirds of EBA, the inflammatory variant develops resembling BP, MMP, or LAD (<xref rid="B149" ref-type="bibr">149</xref>, <xref rid="B152" ref-type="bibr">152</xref>). The diagnostic gold standards are direct immunogold electron microscopy, a methods nowadays only performed for this purpose in handful of centers, and more conveniently, DIF microscopy (<xref rid="B144" ref-type="bibr">144</xref>). By latter method, diagnosis of EBA can be made when a u-serrated binding pattern is present as detailed above (Figures <xref ref-type="fig" rid="F1">1</xref>, <xref ref-type="fig" rid="F3">3</xref>). Type VII collagen-specific autoantibodies are deposited at the floor of the artificial blister of salt-split human skin using IIF microscopy (Figure <xref ref-type="fig" rid="F2">2</xref> right) and are mostly directed against the noncollagenous (NC)1 domain (<xref rid="B153" ref-type="bibr">153</xref>, <xref rid="B154" ref-type="bibr">154</xref>). Autoantibodies can be detected via Western blotting, using an extract of the human dermis (Figure <xref ref-type="fig" rid="F6">6</xref>). Three assays for the diagnostic detection of serum IgG against type VII collagen are available; two ELISA system using the NC1 domain or both the NC1 and NC2 domains as well as an IIF test based on the Biochip mosaic technology employing human cells that express the recombinant NC1 domain (Figure <xref ref-type="fig" rid="F4">4</xref>) (<xref rid="B50" ref-type="bibr">50</xref>, <xref rid="B51" ref-type="bibr">51</xref>, <xref rid="B75" ref-type="bibr">75</xref>). Anti-type VII collagen ELISA values were shown to correlate with disease activity (<xref rid="B155" ref-type="bibr">155</xref>), thus, like in PV, PF, and BP, the respective ELISA systems are useful tools not only for the diagnosis of the disease but also to guide treatment decisions during the course of the diseases. Patients with predominant or exclusive IgA reactivity against type VII collagen are usually classified as IgA EBA following the consensus of an international expert panel (<xref rid="B144" ref-type="bibr">144</xref>, <xref rid="B149" ref-type="bibr">149</xref>, <xref rid="B152" ref-type="bibr">152</xref>, <xref rid="B156" ref-type="bibr">156</xref>, <xref rid="B157" ref-type="bibr">157</xref>).</p></sec><sec><title>Dermatitis herpetiformis</title><p>Dermatitis herpetiformis is an autoimmune disease that always occurs in combination with glutensensitive enteropathy (celiac disease). It is clinically characterized by grouped vesicles and papules and predominantly affects the elbows, buttocks, and knees (<xref rid="B146" ref-type="bibr">146</xref>, <xref rid="B147" ref-type="bibr">147</xref>, <xref rid="B149" ref-type="bibr">149</xref>, <xref rid="B158" ref-type="bibr">158</xref>&#x02013;<xref rid="B160" ref-type="bibr">160</xref>). The autoantigen is the epidermal transglutaminase, however antibodies against gliadin, endomysium, tissue transglutaminase (TG2), and epidermal transglutaminase (TG3) can be detected (<xref rid="B161" ref-type="bibr">161</xref>). The main antibody-subclass is IgA but can be IgG in some patients. In patients under treatment with dapsone or on gluten-restricted diet, autoantibodies against the epidermal transglutaminase are found more frequently than autoantibodies to tissue transglutaminase (<xref rid="B162" ref-type="bibr">162</xref>). The diagnosis is based on the DIF and IIF microscopy findings as well as commercial ELISA systems. Here, IgA (or IgG)-autoantibodies against the epidermal and tissue transglutaminase as well as the deaminated gliadin-analogous fusion (GAF) peptides can be detected (<xref rid="B61" ref-type="bibr">61</xref>, <xref rid="B162" ref-type="bibr">162</xref>).</p></sec></sec><sec id="s8"><title>Author contributions</title><p>MW and ES performed the literature research, acquired and designed the figures and wrote the manuscript. DZ performed literature research and critically revised the manuscript.</p><sec><title>Conflict of interest statement</title><p>DZ and ES have a scientific cooperation with Euroimmun, L&#x000fc;beck. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></sec></body><back><ack><p>We thank Inge Atefi, Dr. Stephanie Freyher, and Marina Kongsbak-Reim, L&#x000fc;beck, for technical assistance. This work was supported by grants from the Deutsche Forschungsgemeinschaft through CRU 303 <italic>Pemphigoid Diseases</italic> (to DZ and ES) and Excellence Cluster 306/2 <italic>Inflammation at Interfaces</italic>.</p></ack><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kasperkiewicz</surname><given-names>M</given-names></name><name><surname>Ellebrecht</surname><given-names>CT</given-names></name><name><surname>Takahashi</surname><given-names>H</given-names></name><name><surname>Yamagami</surname><given-names>J</given-names></name><name><surname>Zillikens</surname><given-names>D</given-names></name><name><surname>Payne</surname><given-names>AS</given-names></name><etal/></person-group>. <article-title>Pemphigus</article-title>. <source>Nat Rev Dis Primer</source> (<year>2017</year>) <volume>3</volume>:<fpage>17026</fpage>. <pub-id pub-id-type="doi">10.1038/nrdp.2017.26</pub-id><?supplied-pmid 28492232?><pub-id pub-id-type="pmid">28492232</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>E</given-names></name><name><surname>Zillikens</surname><given-names>D</given-names></name></person-group>. <article-title>Pemphigoid diseases</article-title>. <source>Lancet Lond Engl.</source> (<year>2013</year>) <volume>381</volume>:<fpage>320</fpage>&#x02013;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(12)61140-4</pub-id><?supplied-pmid 23237497?><pub-id pub-id-type="pmid">23237497</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>E</given-names></name><name><surname>Zillikens</surname><given-names>D</given-names></name></person-group>. <article-title>The diagnosis and treatment of autoimmune blistering skin diseases</article-title>. <source>Dtsch Arzteblatt Int.</source> (<year>2011</year>) <volume>108</volume>:<fpage>399</fpage>&#x02013;<lpage>405</lpage>. <pub-id pub-id-type="doi">10.3238/arztebl.2011.0405</pub-id><?supplied-pmid 21712975?><pub-id pub-id-type="pmid">21712975</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>E</given-names></name><name><surname>Zillikens</surname><given-names>D</given-names></name></person-group>. <article-title>Modern diagnosis of autoimmune blistering skin diseases</article-title>. <source>Autoimmun Rev.</source> (<year>2010</year>) <volume>10</volume>:<fpage>84</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.autrev.2010.08.007</pub-id><?supplied-pmid 20713186?><pub-id pub-id-type="pmid">20713186</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertram</surname><given-names>F</given-names></name><name><surname>Br&#x000f6;cker</surname><given-names>E-B</given-names></name><name><surname>Zillikens</surname><given-names>D</given-names></name><name><surname>Schmidt</surname><given-names>E</given-names></name></person-group>. <article-title>Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany</article-title>. <source>J Dtsch Dermatol Ges J Ger Soc Dermatol.</source> (<year>2009</year>) <volume>7</volume>:<fpage>434</fpage>&#x02013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1111/j.1610-0387.2008.06976.x</pub-id><?supplied-pmid 19170813?><pub-id pub-id-type="pmid">19170813</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marazza</surname><given-names>G</given-names></name><name><surname>Pham</surname><given-names>HC</given-names></name><name><surname>Sch&#x000e4;rer</surname><given-names>L</given-names></name><name><surname>Pedrazzetti</surname><given-names>PP</given-names></name><name><surname>Hunziker</surname><given-names>T</given-names></name><name><surname>Tr&#x000fc;eb</surname><given-names>RM</given-names></name><etal/></person-group>. <article-title>Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study</article-title>. <source>Br J Dermatol.</source> (<year>2009</year>) <volume>161</volume>:<fpage>861</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2133.2009.09300.x</pub-id><?supplied-pmid 19566661?><pub-id pub-id-type="pmid">19566661</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joly</surname><given-names>P</given-names></name><name><surname>Baricault</surname><given-names>S</given-names></name><name><surname>Sparsa</surname><given-names>A</given-names></name><name><surname>Bernard</surname><given-names>P</given-names></name><name><surname>B&#x000e9;dane</surname><given-names>C</given-names></name><name><surname>Duvert-Lehembre</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Incidence and mortality of bullous pemphigoid in France</article-title>. <source>J Invest Dermatol.</source> (<year>2012</year>) <volume>132</volume>:<fpage>1998</fpage>&#x02013;<lpage>2004</lpage>. <pub-id pub-id-type="doi">10.1038/jid.2012.35</pub-id><?supplied-pmid 22418872?><pub-id pub-id-type="pmid">22418872</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>F&#x000f6;rsti</surname><given-names>A-K</given-names></name><name><surname>Jokelainen</surname><given-names>J</given-names></name><name><surname>Timonen</surname><given-names>M</given-names></name><name><surname>Tasanen</surname><given-names>K</given-names></name></person-group>. <article-title>Increasing incidence of bullous pemphigoid in Northern Finland: a retrospective database study in Oulu University Hospital</article-title>. <source>Br J Dermatol.</source> (<year>2014</year>) <volume>171</volume>:<fpage>1223</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1111/bjd.13189</pub-id><?supplied-pmid 24934834?><pub-id pub-id-type="pmid">24934834</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langan</surname><given-names>SM</given-names></name><name><surname>Smeeth</surname><given-names>L</given-names></name><name><surname>Hubbard</surname><given-names>R</given-names></name><name><surname>Fleming</surname><given-names>KM</given-names></name><name><surname>Smith</surname><given-names>CJP</given-names></name><name><surname>West</surname><given-names>J</given-names></name></person-group>. <article-title>Bullous pemphigoid and pemphigus vulgaris&#x02013;incidence and mortality in the UK: population based cohort study</article-title>. <source>BMJ</source> (<year>2008</year>) <volume>337</volume>:<fpage>a180</fpage>. <pub-id pub-id-type="doi">10.1136/bmj.a180</pub-id><?supplied-pmid 18614511?><pub-id pub-id-type="pmid">18614511</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thorslund</surname><given-names>K</given-names></name><name><surname>Seifert</surname><given-names>O</given-names></name><name><surname>Nilz&#x000e9;n</surname><given-names>K</given-names></name><name><surname>Gr&#x000f6;nhagen</surname><given-names>C</given-names></name></person-group>. <article-title>Incidence of bullous pemphigoid in Sweden 2005-2012: a nationwide population-based cohort study of 3761 patients</article-title>. <source>Arch Dermatol Res.</source> (<year>2017</year>) <volume>309</volume>:<fpage>721</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1007/s00403-017-1778-4</pub-id><?supplied-pmid 28875235?><pub-id pub-id-type="pmid">28875235</pub-id></mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertram</surname><given-names>F</given-names></name><name><surname>Br&#x000c3;cker</surname><given-names>E-B</given-names></name><name><surname>Zillikens</surname><given-names>D</given-names></name><name><surname>Schmidt</surname><given-names>E</given-names></name></person-group>
<article-title>Prospektive Untersuchung der Inzidenz blasenbildender Autoimmundermatosen in Unterfranken</article-title>. <source>J Dtsch Dermatol Ges.</source> (<year>2009</year>) <volume>7</volume>:<fpage>434</fpage>&#x02013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1111/j.1610-0387.2008.06976_supp.x</pub-id><pub-id pub-id-type="pmid">19170813</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>F&#x000f6;rsti</surname><given-names>A-K</given-names></name><name><surname>Huilaja</surname><given-names>L</given-names></name><name><surname>Schmidt</surname><given-names>E</given-names></name><name><surname>Tasanen</surname><given-names>K</given-names></name></person-group>. <article-title>Neurological and psychiatric associations in bullous pemphigoid-more than skin deep?</article-title>
<source>Exp Dermatol.</source> (<year>2017</year>) <volume>26</volume>:<fpage>1228</fpage>&#x02013;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1111/exd.13401</pub-id><?supplied-pmid 28677172?><pub-id pub-id-type="pmid">28677172</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>Z</given-names></name><name><surname>Hsu</surname><given-names>DY</given-names></name><name><surname>Brieva</surname><given-names>J</given-names></name><name><surname>Silverberg</surname><given-names>NB</given-names></name><name><surname>Langan</surname><given-names>SM</given-names></name><name><surname>Silverberg</surname><given-names>JI</given-names></name></person-group>. <article-title>Hospitalization, inpatient burden and comorbidities associated with bullous pemphigoid in the U.S.A</article-title>. <source>Br J Dermatol.</source> (<year>2017</year>) <volume>176</volume>:<fpage>87</fpage>&#x02013;<lpage>99</lpage>. <pub-id pub-id-type="doi">10.1111/bjd.14821</pub-id><?supplied-pmid 27343837?><pub-id pub-id-type="pmid">27343837</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyer</surname><given-names>N</given-names></name><name><surname>Misery</surname><given-names>L</given-names></name></person-group>. <article-title>Geoepidemiologic considerations of auto-immune pemphigus</article-title>. <source>Autoimmun Rev.</source> (<year>2010</year>) <volume>9</volume>:<fpage>A379</fpage>&#x02013;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1016/j.autrev.2009.10.009</pub-id><?supplied-pmid 19895907?><pub-id pub-id-type="pmid">19895907</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kridin</surname><given-names>K</given-names></name></person-group>. <article-title>Pemphigus group: overview, epidemiology, mortality, and comorbidities</article-title>. <source>Immunol Res.</source> (<year>2018</year>) <volume>66</volume>:<fpage>255</fpage>&#x02013;<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1007/s12026-018-8986-7</pub-id><?supplied-pmid 29479654?><pub-id pub-id-type="pmid">29479654</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bastuji-Garin</surname><given-names>S</given-names></name><name><surname>Souissi</surname><given-names>R</given-names></name><name><surname>Blum</surname><given-names>L</given-names></name><name><surname>Turki</surname><given-names>H</given-names></name><name><surname>Nouira</surname><given-names>R</given-names></name><name><surname>Jomaa</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Comparative epidemiology of pemphigus in Tunisia and France: unusual incidence of pemphigus foliaceus in young Tunisian women</article-title>. <source>J Invest Dermatol.</source> (<year>1995</year>) <volume>104</volume>:<fpage>302</fpage>&#x02013;<lpage>405</lpage>. <?supplied-pmid 7829889?><pub-id pub-id-type="pmid">7829889</pub-id></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Culton</surname><given-names>DA</given-names></name><name><surname>Qian</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Rubenstein</surname><given-names>D</given-names></name><name><surname>Aoki</surname><given-names>V</given-names></name><name><surname>Filhio</surname><given-names>GH</given-names></name><etal/></person-group>. <article-title>Advances in pemphigus and its endemic pemphigus foliaceus (Fogo Selvagem) phenotype: a paradigm of human autoimmunity</article-title>. <source>J Autoimmun.</source> (<year>2008</year>) <volume>31</volume>:<fpage>311</fpage>&#x02013;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaut.2008.08.003</pub-id><?supplied-pmid 18838249?><pub-id pub-id-type="pmid">18838249</pub-id></mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>H&#x000fc;bner</surname><given-names>F</given-names></name><name><surname>Recke</surname><given-names>A</given-names></name><name><surname>Zillikens</surname><given-names>D</given-names></name><name><surname>Linder</surname><given-names>R</given-names></name><name><surname>Schmidt</surname><given-names>E</given-names></name></person-group>. <article-title>Prevalence and age distribution of pemphigus and pemphigoid diseases in Germany</article-title>. <source>J Invest Dermatol.</source> (<year>2016</year>) <volume>136</volume>:<fpage>2495</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.jid.2016.07.013</pub-id><?supplied-pmid 27456755?><pub-id pub-id-type="pmid">27456755</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lever</surname><given-names>WF</given-names></name></person-group>
<article-title>Pemphigus: a historical study</article-title>. <source>Arch Dermatol Syphilol.</source> (<year>1942</year>) <volume>46</volume>:<fpage>800</fpage>
<pub-id pub-id-type="doi">10.1001/archderm.1942.01500180020004</pub-id></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lever</surname><given-names>WF</given-names></name></person-group>. <article-title>Pemphigus</article-title>. <source>Medicine</source> (<year>1953</year>) <volume>32</volume>:<fpage>1</fpage>&#x02013;<lpage>123</lpage>. <?supplied-pmid 13024494?><pub-id pub-id-type="pmid">13024494</pub-id></mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beutner</surname><given-names>EH</given-names></name><name><surname>Jordon</surname><given-names>RE</given-names></name></person-group>. <article-title>Demonstration of skin antibodies in sera of pemphigus vulgaris patients by indirect immunofluorescent staining</article-title>. <source>Proc Soc Exp Biol Med.</source> (<year>1964</year>) <volume>117</volume>:<fpage>505</fpage>&#x02013;<lpage>10</lpage>. <?supplied-pmid 14233481?><pub-id pub-id-type="pmid">14233481</pub-id></mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jordon</surname><given-names>RE</given-names></name><name><surname>Beutner</surname><given-names>EH</given-names></name><name><surname>Witebsky</surname><given-names>E</given-names></name><name><surname>Blumental</surname><given-names>G</given-names></name><name><surname>Hale</surname><given-names>WL</given-names></name><name><surname>Lever</surname><given-names>WF</given-names></name></person-group>. <article-title>Basement zone antibodies in bullous pemphigoid</article-title>. <source>JAMA</source> (<year>1967</year>) <volume>200</volume>:<fpage>751</fpage>&#x02013;<lpage>6</lpage>. <?supplied-pmid 4164640?><pub-id pub-id-type="pmid">4164640</pub-id></mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mihai</surname><given-names>S</given-names></name><name><surname>Sitaru</surname><given-names>C</given-names></name></person-group>. <article-title>Immunopathology and molecular diagnosis of autoimmune bullous diseases</article-title>. <source>J Cell Mol Med.</source> (<year>2007</year>) <volume>11</volume>:<fpage>462</fpage>&#x02013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1111/j.1582-4934.2007.00033.x</pub-id><?supplied-pmid 17521373?><pub-id pub-id-type="pmid">17521373</pub-id></mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anhalt</surname><given-names>GJ</given-names></name><name><surname>Labib</surname><given-names>RS</given-names></name><name><surname>Voorhees</surname><given-names>JJ</given-names></name><name><surname>Beals</surname><given-names>TF</given-names></name><name><surname>Diaz</surname><given-names>LA</given-names></name></person-group>. <article-title>Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease</article-title>. <source>N Engl J Med.</source> (<year>1982</year>) <volume>306</volume>:<fpage>1189</fpage>&#x02013;<lpage>96</lpage>. <pub-id pub-id-type="doi">10.1056/NEJM198205203062001</pub-id><?supplied-pmid 7040962?><pub-id pub-id-type="pmid">7040962</pub-id></mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Diaz</surname><given-names>LA</given-names></name><name><surname>Troy</surname><given-names>JL</given-names></name><name><surname>Taylor</surname><given-names>AF</given-names></name><name><surname>Emery</surname><given-names>DJ</given-names></name><name><surname>Fairley</surname><given-names>JA</given-names></name><etal/></person-group>. <article-title>A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180</article-title>. <source>J Clin Invest.</source> (<year>1993</year>) <volume>92</volume>:<fpage>2480</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1172/JCI116856</pub-id><?supplied-pmid 7693763?><pub-id pub-id-type="pmid">7693763</pub-id></mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lazarova</surname><given-names>Z</given-names></name><name><surname>Hsu</surname><given-names>R</given-names></name><name><surname>Yee</surname><given-names>C</given-names></name><name><surname>Yancey</surname><given-names>KB</given-names></name></person-group>. <article-title>Antiepiligrin cicatricial pemphigoid represents an autoimmune response to subunits present in laminin 5 (alpha3beta3gamma2)</article-title>. <source>Br J Dermatol.</source> (<year>1998</year>) <volume>139</volume>:<fpage>791</fpage>&#x02013;<lpage>7</lpage>. <?supplied-pmid 9892943?><pub-id pub-id-type="pmid">9892943</pub-id></mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishie</surname><given-names>W</given-names></name><name><surname>Sawamura</surname><given-names>D</given-names></name><name><surname>Goto</surname><given-names>M</given-names></name><name><surname>Ito</surname><given-names>K</given-names></name><name><surname>Shibaki</surname><given-names>A</given-names></name><name><surname>McMillan</surname><given-names>JR</given-names></name><etal/></person-group>. <article-title>Humanization of autoantigen</article-title>. <source>Nat Med.</source> (<year>2007</year>) <volume>13</volume>:<fpage>378</fpage>&#x02013;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1038/nm1496</pub-id><?supplied-pmid 17322897?><pub-id pub-id-type="pmid">17322897</pub-id></mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulze</surname><given-names>FS</given-names></name><name><surname>Beckmann</surname><given-names>T</given-names></name><name><surname>Nimmerjahn</surname><given-names>F</given-names></name><name><surname>Ishiko</surname><given-names>A</given-names></name><name><surname>Collin</surname><given-names>M</given-names></name><name><surname>K&#x000f6;hl</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Fc&#x003b3; receptors III and IV mediate tissue destruction in a novel adult mouse model of bullous pemphigoid</article-title>. <source>Am J Pathol.</source> (<year>2014</year>) <volume>184</volume>:<fpage>2185</fpage>&#x02013;<lpage>96</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajpath.2014.05.007</pub-id><?supplied-pmid 25043618?><pub-id pub-id-type="pmid">25043618</pub-id></mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heppe</surname><given-names>EN</given-names></name><name><surname>Tofern</surname><given-names>S</given-names></name><name><surname>Schulze</surname><given-names>FS</given-names></name><name><surname>Ishiko</surname><given-names>A</given-names></name><name><surname>Shimizu</surname><given-names>A</given-names></name><name><surname>Sina</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Experimental laminin 332 mucous membrane pemphigoid critically involves C5aR1 and reflects clinical and immunopathological characteristics of the human disease</article-title>. <source>J Invest Dermatol.</source> (<year>2017</year>) <volume>137</volume>:<fpage>1709</fpage>&#x02013;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1016/j.jid.2017.03.037</pub-id><?supplied-pmid 28456612?><pub-id pub-id-type="pmid">28456612</pub-id></mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stanley</surname><given-names>JR</given-names></name><name><surname>Amagai</surname><given-names>M</given-names></name></person-group>. <article-title>Pemphigus, bullous impetigo, and the staphylococcal scalded-skin syndrome</article-title>. <source>N Engl J Med.</source> (<year>2006</year>) <volume>355</volume>:<fpage>1800</fpage>&#x02013;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMra061111</pub-id><?supplied-pmid 17065642?><pub-id pub-id-type="pmid">17065642</pub-id></mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Witte</surname><given-names>M</given-names></name><name><surname>Koga</surname><given-names>H</given-names></name><name><surname>Hashimoto</surname><given-names>T</given-names></name><name><surname>Ludwig</surname><given-names>RJ</given-names></name><name><surname>Bieber</surname><given-names>K</given-names></name></person-group>. <article-title>Discovering potential drug-targets for personalized treatment of autoimmune disorders-what we learn from epidermolysis bullosa acquisita</article-title>. <source>Expert Opin Ther Targets</source> (<year>2016</year>) <volume>20</volume>:<fpage>985</fpage>&#x02013;<lpage>98</lpage>. <pub-id pub-id-type="doi">10.1517/14728222.2016.1148686</pub-id><?supplied-pmid 26838687?><pub-id pub-id-type="pmid">26838687</pub-id></mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Sui</surname><given-names>W</given-names></name><name><surname>Zhao</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Thresher</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Subepidermal blistering induced by human autoantibodies to BP180 requires innate immune players in a humanized bullous pemphigoid mouse model</article-title>. <source>J Autoimmun.</source> (<year>2008</year>) <volume>31</volume>:<fpage>331</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaut.2008.08.009</pub-id><?supplied-pmid 18922680?><pub-id pub-id-type="pmid">18922680</pub-id></mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spindler</surname><given-names>V</given-names></name><name><surname>Waschke</surname><given-names>J</given-names></name></person-group>. <article-title>Pemphigus-A disease of desmosome dysfunction caused by multiple mechanisms</article-title>. <source>Front Immunol.</source> (<year>2018</year>) <volume>9</volume>:<fpage>136</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2018.00136</pub-id><?supplied-pmid 29449846?><pub-id pub-id-type="pmid">29449846</pub-id></mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spindler</surname><given-names>V</given-names></name><name><surname>Eming</surname><given-names>R</given-names></name><name><surname>Schmidt</surname><given-names>E</given-names></name><name><surname>Amagai</surname><given-names>M</given-names></name><name><surname>Grando</surname><given-names>S</given-names></name><name><surname>Jonkman</surname><given-names>MF</given-names></name><etal/></person-group>. <article-title>Mechanisms causing loss of keratinocyte cohesion in pemphigus</article-title>. <source>J Invest Dermatol.</source> (<year>2018</year>) <volume>138</volume>:<fpage>32</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.jid.2017.06.022</pub-id><?supplied-pmid 29037765?><pub-id pub-id-type="pmid">29037765</pub-id></mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boraiy</surname><given-names>L</given-names></name><name><surname>Fontao</surname><given-names>L</given-names></name></person-group>. <article-title>Michel's transport medium as an alternative to liquid nitrogen for PCR analysis of skin biopsy specimens</article-title>. <source>Dermatopathology</source> (<year>2014</year>) <volume>1</volume>:<fpage>70</fpage>&#x02013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1159/000368347</pub-id><?supplied-pmid 27047924?><pub-id pub-id-type="pmid">27047924</pub-id></mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>E</given-names></name><name><surname>Goebeler</surname><given-names>M</given-names></name><name><surname>Hertl</surname><given-names>M</given-names></name><name><surname>S&#x000e1;rdy</surname><given-names>M</given-names></name><name><surname>Sitaru</surname><given-names>C</given-names></name><name><surname>Eming</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>S2k guideline for the diagnosis of pemphigus vulgaris/foliaceus and bullous pemphigoid</article-title>. <source>J Dtsch Dermatol Ges.</source> (<year>2015</year>) <volume>13</volume>:<fpage>713</fpage>&#x02013;<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1111/ddg.12612</pub-id><?supplied-pmid 26110729?><pub-id pub-id-type="pmid">26110729</pub-id></mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vodegel</surname><given-names>RM</given-names></name><name><surname>Jonkman</surname><given-names>MF</given-names></name><name><surname>Pas</surname><given-names>HH</given-names></name><name><surname>de Jong</surname><given-names>MCJM</given-names></name></person-group>. <article-title>U-serrated immunodeposition pattern differentiates type VII collagen targeting bullous diseases from other subepidermal bullous autoimmune diseases</article-title>. <source>Br J Dermatol.</source> (<year>2004</year>) <volume>151</volume>:<fpage>112</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2133.2004.06006.x</pub-id><?supplied-pmid 15270879?><pub-id pub-id-type="pmid">15270879</pub-id></mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terra</surname><given-names>JB</given-names></name><name><surname>Pas</surname><given-names>HH</given-names></name><name><surname>Hertl</surname><given-names>M</given-names></name><name><surname>Dikkers</surname><given-names>FG</given-names></name><name><surname>Kamminga</surname><given-names>N</given-names></name><name><surname>Jonkman</surname><given-names>MF</given-names></name></person-group>. <article-title>Immunofluorescence serration pattern analysis as a diagnostic criterion in antilaminin-332 mucous membrane pemphigoid: immunopathological findings and clinical experience in 10 Dutch patients</article-title>. <source>Br J Dermatol.</source> (<year>2011</year>) <volume>165</volume>:<fpage>815</fpage>&#x02013;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2133.2011.10474.x</pub-id><?supplied-pmid 21692774?><pub-id pub-id-type="pmid">21692774</pub-id></mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meijer</surname><given-names>JM</given-names></name><name><surname>Atefi</surname><given-names>I</given-names></name><name><surname>Diercks</surname><given-names>GFH</given-names></name><name><surname>Vorobyev</surname><given-names>A</given-names></name><name><surname>Zuiderveen</surname><given-names>J</given-names></name><name><surname>Meijer</surname><given-names>HJ</given-names></name><etal/></person-group>. <article-title>Serration pattern analysis for differentiating epidermolysis bullosa acquisita from other pemphigoid diseases</article-title>. <source>J Am Acad Dermatol.</source> (<year>2018</year>) <volume>78</volume>:<fpage>754</fpage>&#x02013;<lpage>9.e6</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaad.2017.11.029</pub-id><?supplied-pmid 29154993?><pub-id pub-id-type="pmid">29154993</pub-id></mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lemcke</surname><given-names>S</given-names></name><name><surname>Sokolowski</surname><given-names>S</given-names></name><name><surname>Rieckhoff</surname><given-names>N</given-names></name><name><surname>Buschtez</surname><given-names>M</given-names></name><name><surname>Kaffka</surname><given-names>C</given-names></name><name><surname>Winter-Keil</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Automated direct immunofluorescence analyses of skin biopsies</article-title>. <source>J Cutan Pathol.</source> (<year>2016</year>) <volume>43</volume>:<fpage>227</fpage>&#x02013;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1111/cup.12637</pub-id><?supplied-pmid 26454250?><pub-id pub-id-type="pmid">26454250</pub-id></mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>S&#x000e1;rdy</surname><given-names>M</given-names></name><name><surname>Kostaki</surname><given-names>D</given-names></name><name><surname>Varga</surname><given-names>R</given-names></name><name><surname>Peris</surname><given-names>K</given-names></name><name><surname>Ruzicka</surname><given-names>T</given-names></name></person-group>. <article-title>Comparative study of direct and indirect immunofluorescence and of bullous pemphigoid 180 and 230 enzyme-linked immunosorbent assays for diagnosis of bullous pemphigoid</article-title>. <source>J Am Acad Dermatol.</source> (<year>2013</year>) <volume>69</volume>:<fpage>748</fpage>&#x02013;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaad.2013.07.009</pub-id><?supplied-pmid 23969034?><pub-id pub-id-type="pmid">23969034</pub-id></mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>PPL</given-names></name><name><surname>Thng</surname><given-names>STG</given-names></name><name><surname>Mohamed</surname><given-names>K</given-names></name><name><surname>Tan</surname><given-names>SH</given-names></name></person-group>. <article-title>Comparison of desmoglein ELISA and indirect immunofluorescence using two substrates (monkey oesophagus and normal human skin) in the diagnosis of pemphigus</article-title>. <source>Australas J Dermatol.</source> (<year>2005</year>) <volume>46</volume>:<fpage>239</fpage>&#x02013;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1111/j.1440-0960.2005.00191.x</pub-id><?supplied-pmid 16197422?><pub-id pub-id-type="pmid">16197422</pub-id></mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harman</surname><given-names>KE</given-names></name><name><surname>Gratian</surname><given-names>MJ</given-names></name><name><surname>Bhogal</surname><given-names>BS</given-names></name><name><surname>Challacombe</surname><given-names>SJ</given-names></name><name><surname>Black</surname><given-names>MM</given-names></name></person-group>. <article-title>The use of two substrates to improve the sensitivity of indirect immunofluorescence in the diagnosis of pemphigus</article-title>. <source>Br J Dermatol.</source> (<year>2000</year>) <volume>142</volume>:<fpage>1135</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1046/j.1365-2133.2000.03538.x</pub-id><?supplied-pmid 10848736?><pub-id pub-id-type="pmid">10848736</pub-id></mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oyama</surname><given-names>N</given-names></name><name><surname>Bhogal</surname><given-names>BS</given-names></name><name><surname>Carrington</surname><given-names>P</given-names></name><name><surname>Gratian</surname><given-names>MJ</given-names></name><name><surname>Black</surname><given-names>MM</given-names></name></person-group>. <article-title>Human placental amnion is a novel substrate for detecting autoantibodies in autoimmune bullous diseases by immunoblotting</article-title>. <source>Br J Dermatol.</source> (<year>2003</year>) <volume>148</volume>:<fpage>939</fpage>&#x02013;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1046/j.1365-2133.2003.05316.x</pub-id><?supplied-pmid 12786824?><pub-id pub-id-type="pmid">12786824</pub-id></mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Machado</surname><given-names>P</given-names></name><name><surname>Michalaki</surname><given-names>H</given-names></name><name><surname>Roche</surname><given-names>P</given-names></name><name><surname>Gaucherand</surname><given-names>M</given-names></name><name><surname>Thivolet</surname><given-names>J</given-names></name><name><surname>Nicolas</surname><given-names>JF</given-names></name></person-group>. <article-title>Serological diagnosis of bullous pemphigoid (BP): comparison of the sensitivity of indirect immunofluorescence on salt-split skin to immunoblotting</article-title>. <source>Br J Dermatol</source> (<year>1992</year>) <volume>126</volume>:<fpage>236</fpage>&#x02013;<lpage>241</lpage>. <?supplied-pmid 1554599?><pub-id pub-id-type="pmid">1554599</pub-id></mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>E</given-names></name><name><surname>D&#x000e4;hnrich</surname><given-names>C</given-names></name><name><surname>Rosemann</surname><given-names>A</given-names></name><name><surname>Probst</surname><given-names>C</given-names></name><name><surname>Komorowski</surname><given-names>L</given-names></name><name><surname>Saschenbrecker</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Novel ELISA systems for antibodies to desmoglein 1 and 3: correlation of disease activity with serum autoantibody levels in individual pemphigus patients</article-title>. <source>Exp Dermatol.</source> (<year>2010</year>) <volume>19</volume>:<fpage>458</fpage>&#x02013;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1111/j.1600-0625.2010.01069.x</pub-id><?supplied-pmid 20163452?><pub-id pub-id-type="pmid">20163452</pub-id></mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sitaru</surname><given-names>C</given-names></name><name><surname>D&#x000e4;hnrich</surname><given-names>C</given-names></name><name><surname>Probst</surname><given-names>C</given-names></name><name><surname>Komorowski</surname><given-names>L</given-names></name><name><surname>Bl&#x000f6;cker</surname><given-names>I</given-names></name><name><surname>Schmidt</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Enzyme-linked immunosorbent assay using multimers of the 16th non-collagenous domain of the BP180 antigen for sensitive and specific detection of pemphigoid autoantibodies</article-title>. <source>Exp Dermatol.</source> (<year>2007</year>) <volume>16</volume>:<fpage>770</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1111/j.1600-0625.2007.00592.x</pub-id><?supplied-pmid 17697150?><pub-id pub-id-type="pmid">17697150</pub-id></mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>M</given-names></name><name><surname>Amagai</surname><given-names>M</given-names></name><name><surname>Kuroda-Kinoshita</surname><given-names>K</given-names></name><name><surname>Hashimoto</surname><given-names>T</given-names></name><name><surname>Shirakata</surname><given-names>Y</given-names></name><name><surname>Hashimoto</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>BP180 ELISA using bacterial recombinant NC16a protein as a diagnostic and monitoring tool for bullous pemphigoid</article-title>. <source>J Dermatol Sci.</source> (<year>2002</year>) <volume>30</volume>:<fpage>224</fpage>&#x02013;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1016/S0923-1811(02)00109-3</pub-id><?supplied-pmid 12443845?><pub-id pub-id-type="pmid">12443845</pub-id></mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshida</surname><given-names>M</given-names></name><name><surname>Hamada</surname><given-names>T</given-names></name><name><surname>Amagai</surname><given-names>M</given-names></name><name><surname>Hashimoto</surname><given-names>K</given-names></name><name><surname>Uehara</surname><given-names>R</given-names></name><name><surname>Yamaguchi</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Enzyme-linked immunosorbent assay using bacterial recombinant proteins of human BP230 as a diagnostic tool for bullous pemphigoid</article-title>. <source>J Dermatol Sci.</source> (<year>2006</year>) <volume>41</volume>:<fpage>21</fpage>&#x02013;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1016/j.jdermsci.2005.11.002</pub-id><?supplied-pmid 16364599?><pub-id pub-id-type="pmid">16364599</pub-id></mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Komorowski</surname><given-names>L</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>R</given-names></name><name><surname>Vorobyev</surname><given-names>A</given-names></name><name><surname>Probst</surname><given-names>C</given-names></name><name><surname>Recke</surname><given-names>A</given-names></name><name><surname>Jonkman</surname><given-names>MF</given-names></name><etal/></person-group>. <article-title>Sensitive and specific assays for routine serological diagnosis of epidermolysis bullosa acquisita</article-title>. <source>J Am Acad Dermatol.</source> (<year>2013</year>) <volume>68</volume>:<fpage>e89</fpage>&#x02013;<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaad.2011.12.032</pub-id><?supplied-pmid 22341608?><pub-id pub-id-type="pmid">22341608</pub-id></mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saleh</surname><given-names>MA</given-names></name><name><surname>Ishii</surname><given-names>K</given-names></name><name><surname>Kim</surname><given-names>Y-J</given-names></name><name><surname>Murakami</surname><given-names>A</given-names></name><name><surname>Ishii</surname><given-names>N</given-names></name><name><surname>Hashimoto</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Development of NC1 and NC2 domains of type VII collagen ELISA for the diagnosis and analysis of the time course of epidermolysis bullosa acquisita patients</article-title>. <source>J Dermatol Sci.</source> (<year>2011</year>) <volume>62</volume>:<fpage>169</fpage>&#x02013;<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1016/j.jdermsci.2011.03.003</pub-id><?supplied-pmid 21482078?><pub-id pub-id-type="pmid">21482078</pub-id></mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bl&#x000f6;cker</surname><given-names>IM</given-names></name><name><surname>D&#x000e4;hnrich</surname><given-names>C</given-names></name><name><surname>Probst</surname><given-names>C</given-names></name><name><surname>Komorowski</surname><given-names>L</given-names></name><name><surname>Saschenbrecker</surname><given-names>S</given-names></name><name><surname>Schlumberger</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Epitope mapping of BP230 leading to a novel enzyme-linked immunosorbent assay for autoantibodies in bullous pemphigoid</article-title>. <source>Br J Dermatol</source> (<year>2012</year>) <volume>166</volume>:<fpage>964</fpage>&#x02013;<lpage>970</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2133.2012.10820.x</pub-id><?supplied-pmid 22242606?><pub-id pub-id-type="pmid">22242606</pub-id></mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tampoia</surname><given-names>M</given-names></name><name><surname>Giavarina</surname><given-names>D</given-names></name><name><surname>Di Giorgio</surname><given-names>C</given-names></name><name><surname>Bizzaro</surname><given-names>N</given-names></name></person-group>. <article-title>Diagnostic accuracy of enzyme-linked immunosorbent assays (ELISA) to detect anti-skin autoantibodies in autoimmune blistering skin diseases: a systematic review and meta-analysis</article-title>. <source>Autoimmun Rev.</source> (<year>2012</year>) <volume>12</volume>:<fpage>121</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.autrev.2012.07.006</pub-id><?supplied-pmid 22781589?><pub-id pub-id-type="pmid">22781589</pub-id></mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powell</surname><given-names>AM</given-names></name><name><surname>Sakuma-Oyama</surname><given-names>Y</given-names></name><name><surname>Oyama</surname><given-names>N</given-names></name><name><surname>Albert</surname><given-names>S</given-names></name><name><surname>Bhogal</surname><given-names>B</given-names></name><name><surname>Kaneko</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Usefulness of BP180 NC16a enzyme-linked immunosorbent assay in the serodiagnosis of pemphigoid gestationis and in differentiating between pemphigoid gestationis and pruritic urticarial papules and plaques of pregnancy</article-title>. <source>Arch Dermatol.</source> (<year>2005</year>) <volume>141</volume>:<fpage>705</fpage>&#x02013;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1001/archderm.141.6.705</pub-id><?supplied-pmid 15967916?><pub-id pub-id-type="pmid">15967916</pub-id></mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al Saif</surname><given-names>F</given-names></name><name><surname>Jouen</surname><given-names>F</given-names></name><name><surname>Hebert</surname><given-names>V</given-names></name><name><surname>Chiavelli</surname><given-names>H</given-names></name><name><surname>Darwish</surname><given-names>B</given-names></name><name><surname>Duvert-Lehembre</surname><given-names>S</given-names></name><etal/><name><surname>French</surname><given-names>Study Group on Autoimmune Bullous Skin Diseases</given-names></name></person-group>. <article-title>Sensitivity and specificity of BP180 NC16A enzyme-linked immunosorbent assay for the diagnosis of pemphigoid gestationis</article-title>. <source>J Am Acad Dermatol.</source> (<year>2017</year>) <volume>76</volume>:<fpage>560</fpage>&#x02013;<lpage>2</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaad.2016.09.030</pub-id><?supplied-pmid 28212762?><pub-id pub-id-type="pmid">28212762</pub-id></mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charneux</surname><given-names>J</given-names></name><name><surname>Lorin</surname><given-names>J</given-names></name><name><surname>Vitry</surname><given-names>F</given-names></name><name><surname>Antonicelli</surname><given-names>F</given-names></name><name><surname>Reguiai</surname><given-names>Z</given-names></name><name><surname>Barbe</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Usefulness of BP230 and BP180-NC16a enzyme-linked immunosorbent assays in the initial diagnosis of bullous pemphigoid: a retrospective study of 138 patients</article-title>. <source>Arch Dermatol.</source> (<year>2011</year>) <volume>147</volume>:<fpage>286</fpage>&#x02013;<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1001/archdermatol.2011.23</pub-id><?supplied-pmid 21422334?><pub-id pub-id-type="pmid">21422334</pub-id></mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roussel</surname><given-names>A</given-names></name><name><surname>Benichou</surname><given-names>J</given-names></name><name><surname>Randriamanantany</surname><given-names>ZA</given-names></name><name><surname>Gilbert</surname><given-names>D</given-names></name><name><surname>Drenovska</surname><given-names>K</given-names></name><name><surname>Houivet</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Enzyme-linked immunosorbent assay for the combination of bullous pemphigoid antigens 1 and 2 in the diagnosis of bullous pemphigoid</article-title>. <source>Arch Dermatol.</source> (<year>2011</year>) <volume>147</volume>:<fpage>293</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1001/archdermatol.2011.21</pub-id><?supplied-pmid 21422336?><pub-id pub-id-type="pmid">21422336</pub-id></mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishii</surname><given-names>K</given-names></name><name><surname>Amagai</surname><given-names>M</given-names></name><name><surname>Hall</surname><given-names>RP</given-names></name><name><surname>Hashimoto</surname><given-names>T</given-names></name><name><surname>Takayanagi</surname><given-names>A</given-names></name><name><surname>Gamou</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins</article-title>. <source>J Immunol.</source> (<year>1997</year>) <volume>159</volume>:<fpage>2010</fpage>&#x02013;<lpage>7</lpage>. <?supplied-pmid 9257868?><pub-id pub-id-type="pmid">9257868</pub-id></mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harman</surname><given-names>KE</given-names></name><name><surname>Seed</surname><given-names>PT</given-names></name><name><surname>Gratian</surname><given-names>MJ</given-names></name><name><surname>Bhogal</surname><given-names>BS</given-names></name><name><surname>Challacombe</surname><given-names>SJ</given-names></name><name><surname>Black</surname><given-names>MM</given-names></name></person-group>. <article-title>The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels</article-title>. <source>Br J Dermatol.</source> (<year>2001</year>) <volume>144</volume>:<fpage>775</fpage>&#x02013;<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1046/j.1365-2133.2001.04132.x</pub-id><?supplied-pmid 11298536?><pub-id pub-id-type="pmid">11298536</pub-id></mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Probst</surname><given-names>C</given-names></name><name><surname>Schlumberger</surname><given-names>W</given-names></name><name><surname>St&#x000f6;cker</surname><given-names>W</given-names></name><name><surname>Recke</surname><given-names>A</given-names></name><name><surname>Schmidt</surname><given-names>E</given-names></name><name><surname>Hashimoto</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Development of ELISA for the specific determination of autoantibodies against envoplakin and periplakin in paraneoplastic pemphigus</article-title>. <source>Clin Chim Acta</source> (<year>2009</year>) <volume>410</volume>:<fpage>13</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.cca.2009.08.022</pub-id><?supplied-pmid 19737550?><pub-id pub-id-type="pmid">19737550</pub-id></mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kasperkiewicz</surname><given-names>M</given-names></name><name><surname>D&#x000e4;hnrich</surname><given-names>C</given-names></name><name><surname>Probst</surname><given-names>C</given-names></name><name><surname>Komorowski</surname><given-names>L</given-names></name><name><surname>St&#x000f6;cker</surname><given-names>W</given-names></name><name><surname>Schlumberger</surname><given-names>W</given-names></name><name><surname>et</surname><given-names>al Novel assay for detecting celiac disease-associated autoantibodies in dermatitis herpetiformis using deamidated gliadin-analogous fusion peptides</given-names></name></person-group>
<source>J Am Acad Dermatol.</source> (<year>2012</year>) <volume>66</volume>:<fpage>583</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaad.2011.02.025</pub-id><pub-id pub-id-type="pmid">21840083</pub-id></mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>M&#x000fc;ller</surname><given-names>R</given-names></name><name><surname>Heber</surname><given-names>B</given-names></name><name><surname>Hashimoto</surname><given-names>T</given-names></name><name><surname>Messer</surname><given-names>G</given-names></name><name><surname>M&#x000fc;llegger</surname><given-names>R</given-names></name><name><surname>Niedermeier</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Autoantibodies against desmocollins in European patients with pemphigus</article-title>. <source>Clin Exp Dermatol.</source> (<year>2009</year>) <volume>34</volume>:<fpage>898</fpage>&#x02013;<lpage>903</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2230.2009.03241.x</pub-id><?supplied-pmid 19456767?><pub-id pub-id-type="pmid">19456767</pub-id></mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishii</surname><given-names>N</given-names></name><name><surname>Teye</surname><given-names>K</given-names></name><name><surname>Fukuda</surname><given-names>S</given-names></name><name><surname>Uehara</surname><given-names>R</given-names></name><name><surname>Hachiya</surname><given-names>T</given-names></name><name><surname>Koga</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Anti-desmocollin autoantibodies in nonclassical pemphigus</article-title>. <source>Br J Dermatol.</source> (<year>2015</year>) <volume>173</volume>:<fpage>59</fpage>&#x02013;<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1111/bjd.13711</pub-id><?supplied-pmid 25640111?><pub-id pub-id-type="pmid">25640111</pub-id></mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Groth</surname><given-names>S</given-names></name><name><surname>Recke</surname><given-names>A</given-names></name><name><surname>Vafia</surname><given-names>K</given-names></name><name><surname>Ludwig</surname><given-names>RJ</given-names></name><name><surname>Hashimoto</surname><given-names>T</given-names></name><name><surname>Zillikens</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Development of a simple enzyme-linked immunosorbent assay for the detection of autoantibodies in anti-p200 pemphigoid</article-title>. <source>Br J Dermatol.</source> (<year>2011</year>) <volume>164</volume>:<fpage>76</fpage>&#x02013;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2133.2010.10056.x</pub-id><?supplied-pmid 20854435?><pub-id pub-id-type="pmid">20854435</pub-id></mixed-citation></ref><ref id="B65"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dainichi</surname><given-names>T</given-names></name><name><surname>Kurono</surname><given-names>S</given-names></name><name><surname>Ohyama</surname><given-names>B</given-names></name><name><surname>Ishii</surname><given-names>N</given-names></name><name><surname>Sanzen</surname><given-names>N</given-names></name><name><surname>Hayashi</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Anti-laminin gamma-1 pemphigoid</article-title>. <source>Proc Natl Acad Sci USA.</source> (<year>2009</year>) <volume>106</volume>:<fpage>2800</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0809230106</pub-id><?supplied-pmid 19196964?><pub-id pub-id-type="pmid">19196964</pub-id></mixed-citation></ref><ref id="B66"><label>66.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Csorba</surname><given-names>K</given-names></name><name><surname>Schmidt</surname><given-names>S</given-names></name><name><surname>Florea</surname><given-names>F</given-names></name><name><surname>Ishii</surname><given-names>N</given-names></name><name><surname>Hashimoto</surname><given-names>T</given-names></name><name><surname>Hertl</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Development of an ELISA for sensitive and specific detection of IgA autoantibodies against BP180 in pemphigoid diseases</article-title>. <source>Orphanet J Rare Dis.</source> (<year>2011</year>) <volume>6</volume>:<fpage>31</fpage>. <pub-id pub-id-type="doi">10.1186/1750-1172-6-31</pub-id><?supplied-pmid 21619684?><pub-id pub-id-type="pmid">21619684</pub-id></mixed-citation></ref><ref id="B67"><label>67.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Izumi</surname><given-names>K</given-names></name><name><surname>Nishie</surname><given-names>W</given-names></name><name><surname>Mai</surname><given-names>Y</given-names></name><name><surname>Wada</surname><given-names>M</given-names></name><name><surname>Natsuga</surname><given-names>K</given-names></name><name><surname>Ujiie</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Autoantibody Profile Differentiates between Inflammatory and noninflammatory bullous pemphigoid</article-title>. <source>J Invest Dermatol.</source> (<year>2016</year>) <volume>136</volume>:<fpage>2201</fpage>&#x02013;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1016/j.jid.2016.06.622</pub-id><?supplied-pmid 27424319?><pub-id pub-id-type="pmid">27424319</pub-id></mixed-citation></ref><ref id="B68"><label>68.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bekou</surname><given-names>V</given-names></name><name><surname>Thoma-Uszynski</surname><given-names>S</given-names></name><name><surname>Wendler</surname><given-names>O</given-names></name><name><surname>Uter</surname><given-names>W</given-names></name><name><surname>Schwietzke</surname><given-names>S</given-names></name><name><surname>Hunziker</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Detection of laminin 5-specific auto-antibodies in mucous membrane and bullous pemphigoid sera by ELISA</article-title>. <source>J Invest Dermatol.</source> (<year>2005</year>) <volume>124</volume>:<fpage>732</fpage>&#x02013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1111/j.0022-202X.2005.23646.x</pub-id><?supplied-pmid 15816831?><pub-id pub-id-type="pmid">15816831</pub-id></mixed-citation></ref><ref id="B69"><label>69.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernard</surname><given-names>P</given-names></name><name><surname>Antonicelli</surname><given-names>F</given-names></name><name><surname>Bedane</surname><given-names>C</given-names></name><name><surname>Joly</surname><given-names>P</given-names></name><name><surname>Le</surname><given-names>Roux-Villet C</given-names></name><name><surname>Duvert-Lehembre</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Prevalence and clinical significance of anti-laminin 332 autoantibodies detected by a novel enzyme-linked immunosorbent assay in mucous membrane pemphigoid</article-title>. <source>JAMA Dermatol.</source> (<year>2013</year>) <volume>149</volume>:<fpage>533</fpage>&#x02013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1001/jamadermatol.2013.1434</pub-id><?supplied-pmid 23426192?><pub-id pub-id-type="pmid">23426192</pub-id></mixed-citation></ref><ref id="B70"><label>70.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hashimoto</surname><given-names>T</given-names></name><name><surname>Ohzono</surname><given-names>A</given-names></name><name><surname>Teye</surname><given-names>K</given-names></name><name><surname>Numata</surname><given-names>S</given-names></name><name><surname>Hiroyasu</surname><given-names>S</given-names></name><name><surname>Tsuruta</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Detection of IgE autoantibodies to BP180 and BP230 and their relationship to clinical features in bullous pemphigoid</article-title>. <source>Br J Dermatol.</source> (<year>2017</year>) <volume>177</volume>:<fpage>141</fpage>&#x02013;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1111/bjd.15114</pub-id><?supplied-pmid 27716903?><pub-id pub-id-type="pmid">27716903</pub-id></mixed-citation></ref><ref id="B71"><label>71.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Beek</surname><given-names>N</given-names></name><name><surname>L&#x000fc;ttmann</surname><given-names>N</given-names></name><name><surname>Huebner</surname><given-names>F</given-names></name><name><surname>Recke</surname><given-names>A</given-names></name><name><surname>Karl</surname><given-names>I</given-names></name><name><surname>Schulze</surname><given-names>FS</given-names></name><etal/></person-group>. <article-title>Correlation of serum levels of IgE autoantibodies against BP180 with bullous pemphigoid disease activity</article-title>. <source>JAMA Dermatol.</source> (<year>2017</year>) <volume>153</volume>:<fpage>30</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1001/jamadermatol.2016.3357</pub-id><?supplied-pmid 27829102?><pub-id pub-id-type="pmid">27829102</pub-id></mixed-citation></ref><ref id="B72"><label>72.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Messingham</surname><given-names>KAN</given-names></name><name><surname>Noe</surname><given-names>MH</given-names></name><name><surname>Chapman</surname><given-names>MA</given-names></name><name><surname>Giudice</surname><given-names>GJ</given-names></name><name><surname>Fairley</surname><given-names>JA</given-names></name></person-group>. <article-title>A novel ELISA reveals high frequencies of BP180-specific IgE production in bullous pemphigoid</article-title>. <source>J Immunol Methods</source> (<year>2009</year>) <volume>346</volume>:<fpage>18</fpage>&#x02013;<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1016/j.jim.2009.04.013</pub-id><?supplied-pmid 19422829?><pub-id pub-id-type="pmid">19422829</pub-id></mixed-citation></ref><ref id="B73"><label>73.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Zenzo</surname><given-names>G</given-names></name><name><surname>Thoma-Uszynski</surname><given-names>S</given-names></name><name><surname>Fontao</surname><given-names>L</given-names></name><name><surname>Calabresi</surname><given-names>V</given-names></name><name><surname>Hofmann</surname><given-names>SC</given-names></name><name><surname>Hellmark</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid</article-title>. <source>Clin Immunol.</source> (<year>2008</year>) <volume>128</volume>:<fpage>415</fpage>&#x02013;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1016/j.clim.2008.04.012</pub-id><?supplied-pmid 18571472?><pub-id pub-id-type="pmid">18571472</pub-id></mixed-citation></ref><ref id="B74"><label>74.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hofmann</surname><given-names>S</given-names></name><name><surname>Thoma-Uszynski</surname><given-names>S</given-names></name><name><surname>Hunziker</surname><given-names>T</given-names></name><name><surname>Bernard</surname><given-names>P</given-names></name><name><surname>Koebnick</surname><given-names>C</given-names></name><name><surname>Stauber</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Severity and phenotype of bullous pemphigoid relate to autoantibody profile against the NH2- and COOH-terminal regions of the BP180 ectodomain</article-title>. <source>J Invest Dermatol.</source> (<year>2002</year>) <volume>119</volume>:<fpage>1065</fpage>&#x02013;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1046/j.1523-1747.2002.19529.x</pub-id><?supplied-pmid 12445194?><pub-id pub-id-type="pmid">12445194</pub-id></mixed-citation></ref><ref id="B75"><label>75.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Beek</surname><given-names>N</given-names></name><name><surname>D&#x000e4;hnrich</surname><given-names>C</given-names></name><name><surname>Johannsen</surname><given-names>N</given-names></name><name><surname>Lemcke</surname><given-names>S</given-names></name><name><surname>Goletz</surname><given-names>S</given-names></name><name><surname>H&#x000fc;bner</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Prospective studies on the routine use of a novel multivariant enzyme-linked immunosorbent assay for the diagnosis of autoimmune bullous diseases</article-title>. <source>J Am Acad Dermatol.</source> (<year>2017</year>) <volume>76</volume>:<fpage>889</fpage>&#x02013;<lpage>94.e5</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaad.2016.11.002</pub-id><?supplied-pmid 28038887?><pub-id pub-id-type="pmid">28038887</pub-id></mixed-citation></ref><ref id="B76"><label>76.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horv&#x000e1;th</surname><given-names>ON</given-names></name><name><surname>Varga</surname><given-names>R</given-names></name><name><surname>Kaneda</surname><given-names>M</given-names></name><name><surname>Schmidt</surname><given-names>E</given-names></name><name><surname>Ruzicka</surname><given-names>T</given-names></name><name><surname>S&#x000e1;rdy</surname><given-names>M</given-names></name></person-group>. <article-title>Diagnostic performance of the &#x0201c;MESACUP anti-Skin profile TEST</article-title>.&#x0201d; <source>Eur J Dermatol.</source> (<year>2016</year>) <volume>26</volume>:<fpage>56</fpage>&#x02013;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1684/ejd.2015.2692</pub-id><?supplied-pmid 26771500?><pub-id pub-id-type="pmid">26771500</pub-id></mixed-citation></ref><ref id="B77"><label>77.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Beek</surname><given-names>N</given-names></name><name><surname>Rentzsch</surname><given-names>K</given-names></name><name><surname>Probst</surname><given-names>C</given-names></name><name><surname>Komorowski</surname><given-names>L</given-names></name><name><surname>Kasperkiewicz</surname><given-names>M</given-names></name><name><surname>Fechner</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Serological diagnosis of autoimmune bullous skin diseases: prospective comparison of the BIOCHIP mosaic-based indirect immunofluorescence technique with the conventional multi-step single test strategy</article-title>. <source>Orphanet J Rare Dis.</source> (<year>2012</year>) <volume>7</volume>:<fpage>49</fpage>. <pub-id pub-id-type="doi">10.1186/1750-1172-7-49</pub-id><?supplied-pmid 22876746?><pub-id pub-id-type="pmid">22876746</pub-id></mixed-citation></ref><ref id="B78"><label>78.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tampoia</surname><given-names>M</given-names></name><name><surname>Zucano</surname><given-names>A</given-names></name><name><surname>Villalta</surname><given-names>D</given-names></name><name><surname>Antico</surname><given-names>A</given-names></name><name><surname>Bizzaro</surname><given-names>N</given-names></name></person-group>. <article-title>Anti-skin specific autoantibodies detected by a new immunofluorescence multiplex biochip method in patients with autoimmune bullous diseases</article-title>. <source>Dermatology</source> (<year>2012</year>) <volume>225</volume>:<fpage>37</fpage>&#x02013;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1159/000339776</pub-id><?supplied-pmid 22907099?><pub-id pub-id-type="pmid">22907099</pub-id></mixed-citation></ref><ref id="B79"><label>79.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russo</surname><given-names>I</given-names></name><name><surname>Saponeri</surname><given-names>A</given-names></name><name><surname>Peserico</surname><given-names>A</given-names></name><name><surname>Alaibac</surname><given-names>M</given-names></name></person-group>. <article-title>The use of biochip immunofluorescence microscopy for the diagnosis of Pemphigus vulgaris</article-title>. <source>Acta Histochem.</source> (<year>2014</year>) <volume>116</volume>:<fpage>713</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.acthis.2013.12.012</pub-id><?supplied-pmid 24485334?><pub-id pub-id-type="pmid">24485334</pub-id></mixed-citation></ref><ref id="B80"><label>80.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xuan</surname><given-names>RR</given-names></name><name><surname>Yang</surname><given-names>A</given-names></name><name><surname>Murrell</surname><given-names>DF</given-names></name></person-group>. <article-title>New biochip immunofluorescence test for the serological diagnosis of pemphigus vulgaris and foliaceus: a review of the literature</article-title>. <source>Int J Womens Dermatol.</source> (<year>2018</year>) <volume>4</volume>:<fpage>102</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijwd.2017.10.001</pub-id><?supplied-pmid 29872685?><pub-id pub-id-type="pmid">29872685</pub-id></mixed-citation></ref><ref id="B81"><label>81.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marzano</surname><given-names>AV</given-names></name><name><surname>Cozzani</surname><given-names>E</given-names></name><name><surname>Biasin</surname><given-names>M</given-names></name><name><surname>Russo</surname><given-names>I</given-names></name><name><surname>Alaibac</surname><given-names>M</given-names></name></person-group>. <article-title>The use of Biochip immunofluorescence microscopy for the serological diagnosis of epidermolysis bullosa acquisita</article-title>. <source>Arch Dermatol Res.</source> (<year>2016</year>) <volume>308</volume>:<fpage>273</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1007/s00403-016-1632-0</pub-id><?supplied-pmid 26895535?><pub-id pub-id-type="pmid">26895535</pub-id></mixed-citation></ref><ref id="B82"><label>82.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mindorf</surname><given-names>S</given-names></name><name><surname>Dettmann</surname><given-names>IM</given-names></name><name><surname>Kr&#x000fc;ger</surname><given-names>S</given-names></name><name><surname>Fuhrmann</surname><given-names>T</given-names></name><name><surname>Rentzsch</surname><given-names>K</given-names></name><name><surname>Karl</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Routine detection of serum antidesmocollin autoantibodies is only useful in patients with atypical pemphigus</article-title>. <source>Exp Dermatol.</source> (<year>2017</year>) <volume>26</volume>:<fpage>1267</fpage>&#x02013;<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1111/exd.13409</pub-id><?supplied-pmid 28815795?><pub-id pub-id-type="pmid">28815795</pub-id></mixed-citation></ref><ref id="B83"><label>83.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goletz</surname><given-names>S</given-names></name><name><surname>Probst</surname><given-names>C</given-names></name><name><surname>Komorowski</surname><given-names>L</given-names></name><name><surname>Schlumberger</surname><given-names>W</given-names></name><name><surname>Fechner</surname><given-names>K</given-names></name><name><surname>van Beek</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Sensitive and specific assay for the serological diagnosis of anti-laminin 332 mucous membrane pemphigoid</article-title>. <source>Br J Dermatol.</source> (<year>2018</year>) <pub-id pub-id-type="doi">10.1111/bjd.17202</pub-id>. [Epub ahead of print].<?supplied-pmid 30216412?><pub-id pub-id-type="pmid">30216412</pub-id></mixed-citation></ref><ref id="B84"><label>84.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zimmermann</surname><given-names>J</given-names></name><name><surname>Bahmer</surname><given-names>F</given-names></name><name><surname>Rose</surname><given-names>C</given-names></name><name><surname>Zillikens</surname><given-names>D</given-names></name><name><surname>Schmidt</surname><given-names>E</given-names></name></person-group>. <article-title>Clinical and immunopathological spectrum of paraneoplastic pemphigus</article-title>. <source>J Dtsch Dermatol Ges.</source> (<year>2010</year>) <volume>8</volume>:<fpage>598</fpage>&#x02013;<lpage>606</lpage>. <pub-id pub-id-type="doi">10.1111/j.1610-0387.2010.07380.x</pub-id><?supplied-pmid 20180886?><pub-id pub-id-type="pmid">20180886</pub-id></mixed-citation></ref><ref id="B85"><label>85.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grootenboer-Mignot</surname><given-names>S</given-names></name><name><surname>Descamps</surname><given-names>V</given-names></name><name><surname>Picard-Dahan</surname><given-names>C</given-names></name><name><surname>Nicaise-Roland</surname><given-names>P</given-names></name><name><surname>Prost-Squarcioni</surname><given-names>C</given-names></name><name><surname>Leroux-Villet</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Place of human amniotic membrane immunoblotting in the diagnosis of autoimmune bullous dermatoses</article-title>. <source>Br J Dermatol.</source> (<year>2010</year>) <volume>162</volume>:<fpage>743</fpage>&#x02013;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2133.2009.09566.x</pub-id><?supplied-pmid 19886889?><pub-id pub-id-type="pmid">19886889</pub-id></mixed-citation></ref><ref id="B86"><label>86.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rashid</surname><given-names>KA</given-names></name><name><surname>Stern</surname><given-names>JNH</given-names></name><name><surname>Ahmed</surname><given-names>AR</given-names></name></person-group>. <article-title>Identification of an epitope within human integrin alpha 6 subunit for the binding of autoantibody and its role in basement membrane separation in oral pemphigoid</article-title>. <source>J Immunol.</source> (<year>2006</year>) <volume>176</volume>:<fpage>1968</fpage>&#x02013;<lpage>77</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.176.3.1968</pub-id><?supplied-pmid 16424229?><pub-id pub-id-type="pmid">16424229</pub-id></mixed-citation></ref><ref id="B87"><label>87.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vodegel</surname><given-names>RM</given-names></name><name><surname>Kiss</surname><given-names>M</given-names></name><name><surname>Cjm De Jong</surname><given-names>M</given-names></name><name><surname>Pas</surname><given-names>HH</given-names></name><name><surname>Altmayer</surname><given-names>A</given-names></name><name><surname>Molnar</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>The use of skin substrates deficient in basement membrane molecules for the diagnosis of subepidermal autoimmune bullous disease</article-title>. <source>Eur J Dermatol EJD.</source> (<year>1998</year>) <volume>8</volume>:<fpage>83</fpage>&#x02013;<lpage>5</lpage>. <?supplied-pmid 9649654?><pub-id pub-id-type="pmid">9649654</pub-id></mixed-citation></ref><ref id="B88"><label>88.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Beek</surname><given-names>N</given-names></name><name><surname>Knuth-Rehr</surname><given-names>D</given-names></name><name><surname>Altmeyer</surname><given-names>P</given-names></name><name><surname>Assaf</surname><given-names>C</given-names></name><name><surname>Babilas</surname><given-names>P</given-names></name><name><surname>Bayerl</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Diagnostics of autoimmune bullous diseases in German dermatology departments</article-title>. <source>J Dtsch Dermatol Ges.</source> (<year>2012</year>) <volume>10</volume>:<fpage>492</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1111/j.1610-0387.2011.07840.x</pub-id><?supplied-pmid 22304433?><pub-id pub-id-type="pmid">22304433</pub-id></mixed-citation></ref><ref id="B89"><label>89.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uzun</surname><given-names>S</given-names></name><name><surname>Durdu</surname><given-names>M</given-names></name></person-group>. <article-title>The specificity and sensitivity of nikolskiy sign in the diagnosis of pemphigus</article-title>. <source>J Am Acad Dermatol.</source> (<year>2006</year>) <volume>54</volume>:<fpage>411</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaad.2005.10.019</pub-id><?supplied-pmid 16488290?><pub-id pub-id-type="pmid">16488290</pub-id></mixed-citation></ref><ref id="B90"><label>90.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>James</surname><given-names>KA</given-names></name><name><surname>Culton</surname><given-names>DA</given-names></name><name><surname>Diaz</surname><given-names>LA</given-names></name></person-group>. <article-title>Diagnosis and clinical features of pemphigus foliaceus</article-title>. <source>Dermatol Clin.</source> (<year>2011</year>) <volume>29</volume>:<fpage>405</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1016/j.det.2011.03.012</pub-id><?supplied-pmid 21605805?><pub-id pub-id-type="pmid">21605805</pub-id></mixed-citation></ref><ref id="B91"><label>91.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stanley</surname><given-names>JR</given-names></name><name><surname>Koulu</surname><given-names>L</given-names></name><name><surname>Klaus-Kovtun</surname><given-names>V</given-names></name><name><surname>Steinberg</surname><given-names>MS</given-names></name></person-group>. <article-title>A monoclonal antibody to the desmosomal glycoprotein desmoglein I binds the same polypeptide as human autoantibodies in pemphigus foliaceus</article-title>. <source>J Immunol.</source> (<year>1986</year>) <volume>136</volume>:<fpage>1227</fpage>&#x02013;<lpage>30</lpage>. <?supplied-pmid 3511144?><pub-id pub-id-type="pmid">3511144</pub-id></mixed-citation></ref><ref id="B92"><label>92.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>K&#x000e1;rp&#x000e1;ti</surname><given-names>S</given-names></name><name><surname>Amagai</surname><given-names>M</given-names></name><name><surname>Prussick</surname><given-names>R</given-names></name><name><surname>Stanley</surname><given-names>JR</given-names></name></person-group>. <article-title>Pemphigus vulgaris antigen is a desmosomal desmoglein</article-title>. <source>Dermatolology</source> (<year>1994</year>) <volume>189</volume> (<issue>Suppl. 1</issue>):<fpage>24</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1159/000246923</pub-id><?supplied-pmid 8049558?><pub-id pub-id-type="pmid">8049558</pub-id></mixed-citation></ref><ref id="B93"><label>93.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anhalt</surname><given-names>GJ</given-names></name></person-group>. <article-title>Paraneoplastic pemphigus</article-title>. <source>Adv Dermatol.</source> (<year>1997</year>) <volume>12</volume>:<fpage>77</fpage>&#x02013;<lpage>96</lpage>; discussion 97. <?supplied-pmid 8973736?><pub-id pub-id-type="pmid">8973736</pub-id></mixed-citation></ref><ref id="B94"><label>94.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anhalt</surname><given-names>GJ</given-names></name></person-group>. <article-title>Paraneoplastic pemphigus</article-title>. <source>J Invest Dermatol Symp Proc.</source> (<year>2004</year>) <volume>9</volume>:<fpage>29</fpage>&#x02013;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1111/j.1087-0024.2004.00832.x</pub-id><?supplied-pmid 14870982?><pub-id pub-id-type="pmid">14870982</pub-id></mixed-citation></ref><ref id="B95"><label>95.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Czernik</surname><given-names>A</given-names></name><name><surname>Wieczorek</surname><given-names>M</given-names></name></person-group>. <article-title>Paraneoplastic pemphigus: a short review</article-title>. <source>Clin Cosmet Investig Dermatol.</source> (<year>2016</year>) <volume>9</volume>:<fpage>291</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.2147/CCID.S100802</pub-id><?supplied-pmid 27729809?><pub-id pub-id-type="pmid">27729809</pub-id></mixed-citation></ref><ref id="B96"><label>96.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akel</surname><given-names>R</given-names></name><name><surname>Fakhri</surname><given-names>G</given-names></name><name><surname>Salem</surname><given-names>R</given-names></name><name><surname>Boulos</surname><given-names>F</given-names></name><name><surname>Habib</surname><given-names>K</given-names></name><name><surname>Tfayli</surname><given-names>A</given-names></name></person-group>. <article-title>Paraneoplastic pemphigus as a first manifestation of an intra-abdominal follicular dendritic cell sarcoma: rare case and review of the literature</article-title>. <source>Case Rep Oncol.</source> (<year>2018</year>) <fpage>353</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1159/000489602</pub-id><?supplied-pmid 29928216?><pub-id pub-id-type="pmid">29928216</pub-id></mixed-citation></ref><ref id="B97"><label>97.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adaszewska</surname><given-names>A</given-names></name><name><surname>Ishii</surname><given-names>N</given-names></name><name><surname>Dwilewicz-Trojaczek</surname><given-names>J</given-names></name><name><surname>Wozniak</surname><given-names>K</given-names></name><name><surname>Hashimoto</surname><given-names>T</given-names></name><name><surname>Kowalewski</surname><given-names>C</given-names></name></person-group>. <article-title>Paraneoplastic pemphigus with anti-desmocollin 3 autoantibodies and chronic lymphocytic leukemia</article-title>. <source>Adv Dermatol Allergol.</source> (<year>2018</year>) <volume>35</volume>:<fpage>113</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.5114/ada.2018.73171</pub-id><?supplied-pmid 29599682?><pub-id pub-id-type="pmid">29599682</pub-id></mixed-citation></ref><ref id="B98"><label>98.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nikolskaia</surname><given-names>OV</given-names></name><name><surname>Nousari</surname><given-names>CH</given-names></name><name><surname>Anhalt</surname><given-names>GJ</given-names></name></person-group>. <article-title>Paraneoplastic pemphigus in association with Castleman's disease</article-title>. <source>Br J Dermatol.</source> (<year>2003</year>) <volume>149</volume>:<fpage>1143</fpage>&#x02013;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2133.2003.05659.x</pub-id><?supplied-pmid 14674890?><pub-id pub-id-type="pmid">14674890</pub-id></mixed-citation></ref><ref id="B99"><label>99.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsuchisaka</surname><given-names>A</given-names></name><name><surname>Numata</surname><given-names>S</given-names></name><name><surname>Teye</surname><given-names>K</given-names></name><name><surname>Natsuaki</surname><given-names>Y</given-names></name><name><surname>Kawakami</surname><given-names>T</given-names></name><name><surname>Takeda</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Epiplakin is a paraneoplastic pemphigus autoantigen and related to bronchiolitis obliterans in Japanese patients</article-title>. <source>J Invest Dermatol.</source> (<year>2016</year>) <volume>136</volume>:<fpage>399</fpage>&#x02013;<lpage>408</lpage>. <pub-id pub-id-type="doi">10.1038/JID.2015.408</pub-id><?supplied-pmid 26802236?><pub-id pub-id-type="pmid">26802236</pub-id></mixed-citation></ref><ref id="B100"><label>100.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schepens</surname><given-names>I</given-names></name><name><surname>Jaunin</surname><given-names>F</given-names></name><name><surname>Begre</surname><given-names>N</given-names></name><name><surname>L&#x000e4;derach</surname><given-names>U</given-names></name><name><surname>Marcus</surname><given-names>K</given-names></name><name><surname>Hashimoto</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>The protease inhibitor alpha-2-macroglobulin-like-1 is the p170 antigen recognized by paraneoplastic pemphigus autoantibodies in human</article-title>. <source>PLoS ONE</source> (<year>2010</year>) <volume>5</volume>:<fpage>e12250</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0012250</pub-id><?supplied-pmid 20805888?><pub-id pub-id-type="pmid">20805888</pub-id></mixed-citation></ref><ref id="B101"><label>101.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Zheng</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Bu</surname><given-names>D</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name></person-group>. <article-title>Epitopes in the linker subdomain region of envoplakin recognized by autoantibodies in paraneoplastic pemphigus patients</article-title>. <source>J Invest Dermatol.</source> (<year>2006</year>) <volume>126</volume>:<fpage>832</fpage>&#x02013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1038/sj.jid.5700198</pub-id><?supplied-pmid 16470171?><pub-id pub-id-type="pmid">16470171</pub-id></mixed-citation></ref><ref id="B102"><label>102.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagata</surname><given-names>Y</given-names></name><name><surname>Karashima</surname><given-names>T</given-names></name><name><surname>Watt</surname><given-names>FM</given-names></name><name><surname>Salmhofer</surname><given-names>W</given-names></name><name><surname>Kanzaki</surname><given-names>T</given-names></name><name><surname>Hashimoto</surname><given-names>T</given-names></name></person-group>. <article-title>Paraneoplastic pemphigus sera react strongly with multiple epitopes on the various regions of envoplakin and periplakin, except for the c-terminal homologous domain of periplakin</article-title>. <source>J Invest Dermatol.</source> (<year>2001</year>) <volume>116</volume>:<fpage>556</fpage>&#x02013;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1046/j.1523-1747.2001.01263.x</pub-id><?supplied-pmid 11286623?><pub-id pub-id-type="pmid">11286623</pub-id></mixed-citation></ref><ref id="B103"><label>103.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stanley</surname><given-names>JR</given-names></name><name><surname>Hawley-Nelson</surname><given-names>P</given-names></name><name><surname>Yuspa</surname><given-names>SH</given-names></name><name><surname>Shevach</surname><given-names>EM</given-names></name><name><surname>Katz</surname><given-names>SI</given-names></name></person-group>. <article-title>Characterization of bullous pemphigoid antigen: a unique basement membrane protein of stratified squamous epithelia</article-title>. <source>Cell</source> (<year>1981</year>) <volume>24</volume>:<fpage>897</fpage>&#x02013;<lpage>903</lpage>. <?supplied-pmid 7018697?><pub-id pub-id-type="pmid">7018697</pub-id></mixed-citation></ref><ref id="B104"><label>104.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwieger-Briel</surname><given-names>A</given-names></name><name><surname>Moellmann</surname><given-names>C</given-names></name><name><surname>Mattulat</surname><given-names>B</given-names></name><name><surname>Schauer</surname><given-names>F</given-names></name><name><surname>Kiritsi</surname><given-names>D</given-names></name><name><surname>Schmidt</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Bullous pemphigoid in infants: characteristics, diagnosis and treatment</article-title>. <source>Orphanet J Rare Dis.</source> (<year>2014</year>) <volume>9</volume>:<fpage>185</fpage>. <pub-id pub-id-type="doi">10.1186/s13023-014-0185-6</pub-id><?supplied-pmid 25491396?><pub-id pub-id-type="pmid">25491396</pub-id></mixed-citation></ref><ref id="B105"><label>105.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kippes</surname><given-names>W</given-names></name><name><surname>Schmidt</surname><given-names>E</given-names></name><name><surname>Roth</surname><given-names>A</given-names></name><name><surname>Rzany</surname><given-names>B</given-names></name><name><surname>Br&#x000f6;cker</surname><given-names>EB</given-names></name><name><surname>Zillikens</surname><given-names>D</given-names></name></person-group>. <article-title>Immunopathologic changes in 115 patients with bullous pemphigoid</article-title>. <source>Hautarzt Z Dermatol Venerol Verwandte Geb.</source> (<year>1999</year>) <volume>50</volume>:<fpage>866</fpage>&#x02013;<lpage>72</lpage>. <?supplied-pmid 10663021?><pub-id pub-id-type="pmid">10663021</pub-id></mixed-citation></ref><ref id="B106"><label>106.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>E</given-names></name><name><surname>della Torre</surname><given-names>R</given-names></name><name><surname>Borradori</surname><given-names>L</given-names></name></person-group>. <article-title>Clinical features and practical diagnosis of bullous pemphigoid</article-title>. <source>Dermatol Clin.</source> (<year>2011</year>) <volume>29</volume>:<fpage>427</fpage>&#x02013;<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1016/j.det.2011.03.010</pub-id><?supplied-pmid 21605808?><pub-id pub-id-type="pmid">21605808</pub-id></mixed-citation></ref><ref id="B107"><label>107.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>della Torre</surname><given-names>R</given-names></name><name><surname>Combescure</surname><given-names>C</given-names></name><name><surname>Cort&#x000e9;s</surname><given-names>B</given-names></name><name><surname>Marazza</surname><given-names>G</given-names></name><name><surname>Beltraminelli</surname><given-names>H</given-names></name><name><surname>Naldi</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Clinical presentation and diagnostic delay in bullous pemphigoid: a prospective nationwide cohort</article-title>. <source>Br J Dermatol.</source> (<year>2012</year>) <volume>167</volume>:<fpage>1111</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2133.2012.11108.x</pub-id><?supplied-pmid 22709136?><pub-id pub-id-type="pmid">22709136</pub-id></mixed-citation></ref><ref id="B108"><label>108.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clap&#x000e9;</surname><given-names>A</given-names></name><name><surname>Muller</surname><given-names>C</given-names></name><name><surname>Gatouillat</surname><given-names>G</given-names></name><name><surname>Le Jan</surname><given-names>S</given-names></name><name><surname>Barbe</surname><given-names>C</given-names></name><name><surname>Pham</surname><given-names>B-N</given-names></name><etal/></person-group>. <article-title>Mucosal involvement in bullous pemphigoid is mostly associated with disease severity and to absence of anti-BP230 autoantibody</article-title>. <source>Front Immunol.</source> (<year>2018</year>) <volume>9</volume>:<fpage>479</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2018.00479</pub-id><?supplied-pmid 29662486?><pub-id pub-id-type="pmid">29662486</pub-id></mixed-citation></ref><ref id="B109"><label>109.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giudice</surname><given-names>GJ</given-names></name><name><surname>Emery</surname><given-names>DJ</given-names></name><name><surname>Diaz</surname><given-names>LA</given-names></name></person-group>. <article-title>Cloning and primary structural analysis of the bullous pemphigoid autoantigen BP180</article-title>. <source>J Invest Dermatol.</source> (<year>1992</year>) <volume>99</volume>:<fpage>243</fpage>&#x02013;<lpage>50</lpage>. <?supplied-pmid 1324962?><pub-id pub-id-type="pmid">1324962</pub-id></mixed-citation></ref><ref id="B110"><label>110.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masunaga</surname><given-names>T</given-names></name><name><surname>Shimizu</surname><given-names>H</given-names></name><name><surname>Yee</surname><given-names>C</given-names></name><name><surname>Borradori</surname><given-names>L</given-names></name><name><surname>Lazarova</surname><given-names>Z</given-names></name><name><surname>Nishikawa</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>The extracellular domain of BPAG2 localizes to anchoring filaments and its carboxyl terminus extends to the lamina densa of normal human epidermal basement membrane</article-title>. <source>J Invest Dermatol.</source> (<year>1997</year>) <volume>109</volume>:<fpage>200</fpage>&#x02013;<lpage>6</lpage>. <?supplied-pmid 9242508?><pub-id pub-id-type="pmid">9242508</pub-id></mixed-citation></ref><ref id="B111"><label>111.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zillikens</surname><given-names>D</given-names></name><name><surname>Rose</surname><given-names>PA</given-names></name><name><surname>Balding</surname><given-names>SD</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Olague-Marchan</surname><given-names>M</given-names></name><name><surname>Diaz</surname><given-names>LA</given-names></name><etal/></person-group>. <article-title>Tight clustering of extracellular BP180 epitopes recognized by bullous pemphigoid autoantibodies</article-title>. <source>J Invest Dermatol.</source> (<year>1997</year>) <volume>109</volume>:<fpage>573</fpage>&#x02013;<lpage>9</lpage>. <?supplied-pmid 9326393?><pub-id pub-id-type="pmid">9326393</pub-id></mixed-citation></ref><ref id="B112"><label>112.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>E</given-names></name><name><surname>Obe</surname><given-names>K</given-names></name><name><surname>Br&#x000f6;cker</surname><given-names>EB</given-names></name><name><surname>Zillikens</surname><given-names>D</given-names></name></person-group>. <article-title>Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid</article-title>. <source>Arch Dermatol.</source> (<year>2000</year>) <volume>136</volume>:<fpage>174</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1001/archderm.136.2.174</pub-id><?supplied-pmid 10677092?><pub-id pub-id-type="pmid">10677092</pub-id></mixed-citation></ref><ref id="B113"><label>113.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Zenzo</surname><given-names>G</given-names></name><name><surname>Grosso</surname><given-names>F</given-names></name><name><surname>Terracina</surname><given-names>M</given-names></name><name><surname>Mariotti</surname><given-names>F</given-names></name><name><surname>De Pit&#x000e0;</surname><given-names>O</given-names></name><name><surname>Owaribe</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Characterization of the anti-BP180 autoantibody reactivity profile and epitope mapping in bullous pemphigoid patients</article-title>. <source>J Invest Dermatol.</source> (<year>2004</year>) <volume>122</volume>:<fpage>103</fpage>&#x02013;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1046/j.0022-202X.2003.22126.x</pub-id><?supplied-pmid 14962097?><pub-id pub-id-type="pmid">14962097</pub-id></mixed-citation></ref><ref id="B114"><label>114.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horv&#x000e1;th</surname><given-names>B</given-names></name><name><surname>Niedermeier</surname><given-names>A</given-names></name><name><surname>Podstawa</surname><given-names>E</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>R</given-names></name><name><surname>Hunzelmann</surname><given-names>N</given-names></name><name><surname>K&#x000e1;rp&#x000e1;ti</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>IgA autoantibodies in the pemphigoids and linear IgA bullous dermatosis</article-title>. <source>Exp Dermatol.</source> (<year>2010</year>) <volume>19</volume>:<fpage>648</fpage>&#x02013;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1111/j.1600-0625.2010.01080.x</pub-id><?supplied-pmid 20500772?><pub-id pub-id-type="pmid">20500772</pub-id></mixed-citation></ref><ref id="B115"><label>115.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kromminga</surname><given-names>A</given-names></name><name><surname>Scheckenbach</surname><given-names>C</given-names></name><name><surname>Georgi</surname><given-names>M</given-names></name><name><surname>Hagel</surname><given-names>C</given-names></name><name><surname>Arndt</surname><given-names>R</given-names></name><name><surname>Christophers</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Patients with bullous pemphigoid and linear IgA disease show a dual IgA and IgG autoimmune response to BP180</article-title>. <source>J Autoimmun.</source> (<year>2000</year>) <volume>15</volume>:<fpage>293</fpage>&#x02013;<lpage>300</lpage>. <pub-id pub-id-type="doi">10.1006/jaut.2000.0437</pub-id><?supplied-pmid 11040070?><pub-id pub-id-type="pmid">11040070</pub-id></mixed-citation></ref><ref id="B116"><label>116.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Beek</surname><given-names>N</given-names></name><name><surname>Schulze</surname><given-names>FS</given-names></name><name><surname>Zillikens</surname><given-names>D</given-names></name><name><surname>Schmidt</surname><given-names>E</given-names></name></person-group>. <article-title>IgE-mediated mechanisms in bullous pemphigoid and other autoimmune bullous diseases</article-title>. <source>Expert Rev Clin Immunol.</source> (<year>2016</year>) <volume>12</volume>:<fpage>267</fpage>&#x02013;<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1586/1744666X.2016.1123092</pub-id><?supplied-pmid 26588556?><pub-id pub-id-type="pmid">26588556</pub-id></mixed-citation></ref><ref id="B117"><label>117.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skaria</surname><given-names>M</given-names></name><name><surname>Jaunin</surname><given-names>F</given-names></name><name><surname>Hunziker</surname><given-names>T</given-names></name><name><surname>Riou</surname><given-names>S</given-names></name><name><surname>Schumann</surname><given-names>H</given-names></name><name><surname>Bruckner-Tuderman</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>IgG autoantibodies from bullous pemphigoid patients recognize multiple antigenic reactive sites located predominantly within the B and C subdomains of the COOH-terminus of BP230</article-title>. <source>J Invest Dermatol.</source> (<year>2000</year>) <volume>114</volume>:<fpage>998</fpage>&#x02013;<lpage>1004</lpage>. <pub-id pub-id-type="doi">10.1046/j.1523-1747.2000.00893.x</pub-id><?supplied-pmid 10771483?><pub-id pub-id-type="pmid">10771483</pub-id></mixed-citation></ref><ref id="B118"><label>118.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamada</surname><given-names>T</given-names></name><name><surname>Nagata</surname><given-names>Y</given-names></name><name><surname>Tomita</surname><given-names>M</given-names></name><name><surname>Salmhofer</surname><given-names>W</given-names></name><name><surname>Hashimoto</surname><given-names>T</given-names></name></person-group>. <article-title>Bullous pemphigoid sera react specifically with various domains of BP230, most frequently with C-terminal domain, by immunoblot analyses using bacterial recombinant proteins covering the entire molecule</article-title>. <source>Exp Dermatol.</source> (<year>2001</year>) <volume>10</volume>:<fpage>256</fpage>&#x02013;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1034/j.1600-0625.2001.100405.x</pub-id><?supplied-pmid 11493314?><pub-id pub-id-type="pmid">11493314</pub-id></mixed-citation></ref><ref id="B119"><label>119.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayakawa</surname><given-names>T</given-names></name><name><surname>Teye</surname><given-names>K</given-names></name><name><surname>Hachiya</surname><given-names>T</given-names></name><name><surname>Uehara</surname><given-names>R</given-names></name><name><surname>Hashiguchi</surname><given-names>M</given-names></name><name><surname>Kawakami</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Clinical and immunological profiles of anti-BP230-type bullous pemphigoid: restriction of epitopes to the C-terminal domain of BP230, shown by novel ELISAs of BP230-domain specific recombinant proteins</article-title>. <source>Eur J Dermatol.</source>
<volume>26</volume>:<fpage>155</fpage>&#x02013;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1684/ejd.2015.2719</pub-id><?supplied-pmid 27087683?><pub-id pub-id-type="pmid">27087683</pub-id></mixed-citation></ref><ref id="B120"><label>120.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daneshpazhooh</surname><given-names>M</given-names></name><name><surname>Ghiasi</surname><given-names>M</given-names></name><name><surname>Lajevardi</surname><given-names>V</given-names></name><name><surname>Nasiri</surname><given-names>N</given-names></name><name><surname>Balighi</surname><given-names>K</given-names></name><name><surname>Teimourpour</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>BPDAI and ABSIS correlate with serum anti-BP180 NC16A IgG but not with anti-BP230 IgG in patients with bullous pemphigoid</article-title>. <source>Arch Dermatol Res.</source> (<year>2018</year>) <volume>310</volume>:<fpage>255</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1007/s00403-018-1817-9</pub-id><pub-id pub-id-type="pmid">29423547</pub-id></mixed-citation></ref><ref id="B121"><label>121.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Intong</surname><given-names>LRA</given-names></name><name><surname>Murrell</surname><given-names>DF</given-names></name></person-group>. <article-title>Pemphigoid gestationis: pathogenesis and clinical features</article-title>. <source>Dermatol Clin.</source> (<year>2011</year>) <volume>29</volume>:<fpage>447</fpage>&#x02013;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1016/j.det.2011.03.002</pub-id><?supplied-pmid 21605810?><pub-id pub-id-type="pmid">21605810</pub-id></mixed-citation></ref><ref id="B122"><label>122.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huilaja</surname><given-names>L</given-names></name><name><surname>M&#x000e4;kikallio</surname><given-names>K</given-names></name><name><surname>Tasanen</surname><given-names>K</given-names></name></person-group>. <article-title>Gestational pemphigoid</article-title>. <source>Orphanet J Rare Dis.</source> (<year>2014</year>) <volume>9</volume>:<fpage>136</fpage>. <pub-id pub-id-type="doi">10.1186/s13023-014-0136-2</pub-id><?supplied-pmid 25178359?><pub-id pub-id-type="pmid">25178359</pub-id></mixed-citation></ref><ref id="B123"><label>123.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sadik</surname><given-names>CD</given-names></name><name><surname>Pas</surname><given-names>HH</given-names></name><name><surname>Bohlmann</surname><given-names>MK</given-names></name><name><surname>Mousavi</surname><given-names>S</given-names></name><name><surname>Benoit</surname><given-names>S</given-names></name><name><surname>S&#x000e1;rdy</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Value of BIOCHIP technology in the serological diagnosis of pemphigoid gestationis</article-title>. <source>Acta Derm Venereol.</source> (<year>2017</year>) <volume>97</volume>:<fpage>128</fpage>&#x02013;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.2340/00015555-2460</pub-id><?supplied-pmid 27174635?><pub-id pub-id-type="pmid">27174635</pub-id></mixed-citation></ref><ref id="B124"><label>124.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chimanovitch</surname><given-names>I</given-names></name><name><surname>Schmidt</surname><given-names>E</given-names></name><name><surname>Messer</surname><given-names>G</given-names></name><name><surname>D&#x000f6;pp</surname><given-names>R</given-names></name><name><surname>Partscht</surname><given-names>K</given-names></name><name><surname>Br&#x000f6;cker</surname><given-names>EB</given-names></name><etal/></person-group>. <article-title>IgG1 and IgG3 are the major immunoglobulin subclasses targeting epitopes within the NC16A domain of BP180 in pemphigoid gestationis</article-title>. <source>J Invest Dermatol.</source> (<year>1999</year>) <volume>113</volume>:<fpage>140</fpage>&#x02013;<lpage>2</lpage>. <pub-id pub-id-type="doi">10.1046/j.1523-1747.1999.00622.x</pub-id><?supplied-pmid 10417635?><pub-id pub-id-type="pmid">10417635</pub-id></mixed-citation></ref><ref id="B125"><label>125.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>LS</given-names></name><name><surname>Ahmed</surname><given-names>AR</given-names></name><name><surname>Anhalt</surname><given-names>GJ</given-names></name><name><surname>Bernauer</surname><given-names>W</given-names></name><name><surname>Cooper</surname><given-names>KD</given-names></name><name><surname>Elder</surname><given-names>MJ</given-names></name><etal/></person-group>. <article-title>The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators</article-title>. <source>Arch Dermatol.</source> (<year>2002</year>) <volume>138</volume>:<fpage>370</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1001/archderm.138.3.370</pub-id><?supplied-pmid 11902988?><pub-id pub-id-type="pmid">11902988</pub-id></mixed-citation></ref><ref id="B126"><label>126.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holtsche</surname><given-names>MM</given-names></name><name><surname>Zillikens</surname><given-names>D</given-names></name><name><surname>Schmidt</surname><given-names>E</given-names></name></person-group>. <article-title>Mucous membrane pemphigoid</article-title>. <source>Hautarzt Z Dermatol Venerol Verwandte Geb.</source> (<year>2018</year>) <volume>69</volume>:<fpage>67</fpage>&#x02013;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1007/s00105-017-4089-y</pub-id><?supplied-pmid 29242962?><pub-id pub-id-type="pmid">29242962</pub-id></mixed-citation></ref><ref id="B127"><label>127.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Witte</surname><given-names>M</given-names></name><name><surname>Zillikens</surname><given-names>D</given-names></name><name><surname>Shimanovich</surname><given-names>I</given-names></name></person-group>
<article-title>Intravenous immunoglobulins for rituximab-resistant mucous membrane pemphigoid</article-title>. <source>J Eur Acad Dermatol Venereol.</source> (<year>2018</year>) <volume>32</volume>:<fpage>e321</fpage>&#x02013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1111/jdv.14873</pub-id></mixed-citation></ref><ref id="B128"><label>128.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>E</given-names></name><name><surname>Skrobek</surname><given-names>C</given-names></name><name><surname>Kromminga</surname><given-names>A</given-names></name><name><surname>Hashimoto</surname><given-names>T</given-names></name><name><surname>Messer</surname><given-names>G</given-names></name><name><surname>Br&#x000f6;cker</surname><given-names>EB</given-names></name><etal/></person-group>. <article-title>Cicatricial pemphigoid: IgA and IgG autoantibodies target epitopes on both intra- and extracellular domains of bullous pemphigoid antigen 180</article-title>. <source>Br J Dermatol.</source> (<year>2001</year>) <volume>145</volume>:<fpage>778</fpage>&#x02013;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1046/j.1365-2133.2001.04471.x</pub-id><?supplied-pmid 11736901?><pub-id pub-id-type="pmid">11736901</pub-id></mixed-citation></ref><ref id="B129"><label>129.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oyama</surname><given-names>N</given-names></name><name><surname>Setterfield</surname><given-names>JF</given-names></name><name><surname>Powell</surname><given-names>AM</given-names></name><name><surname>Sakuma-Oyama</surname><given-names>Y</given-names></name><name><surname>Albert</surname><given-names>S</given-names></name><name><surname>Bhogal</surname><given-names>BS</given-names></name><etal/></person-group>. <article-title>Bullous pemphigoid antigen II (BP180) and its soluble extracellular domains are major autoantigens in mucous membrane pemphigoid: the pathogenic relevance to HLA class II alleles and disease severity</article-title>. <source>Br J Dermatol.</source> (<year>2006</year>) <volume>154</volume>:<fpage>90</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2133.2005.06998.x</pub-id><?supplied-pmid 16403100?><pub-id pub-id-type="pmid">16403100</pub-id></mixed-citation></ref><ref id="B130"><label>130.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Domloge-Hultsch</surname><given-names>N</given-names></name><name><surname>Gammon</surname><given-names>WR</given-names></name><name><surname>Briggaman</surname><given-names>RA</given-names></name><name><surname>Gil</surname><given-names>SG</given-names></name><name><surname>Carter</surname><given-names>WG</given-names></name><name><surname>Yancey</surname><given-names>KB</given-names></name></person-group>. <article-title>Epiligrin, the major human keratinocyte integrin ligand, is a target in both an acquired autoimmune and an inherited subepidermal blistering skin disease</article-title>. <source>J Clin Invest.</source> (<year>1992</year>) <volume>90</volume>:<fpage>1628</fpage>&#x02013;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1172/JCI116033</pub-id><?supplied-pmid 1401088?><pub-id pub-id-type="pmid">1401088</pub-id></mixed-citation></ref><ref id="B131"><label>131.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirtschig</surname><given-names>G</given-names></name><name><surname>Marinkovich</surname><given-names>MP</given-names></name><name><surname>Burgeson</surname><given-names>RE</given-names></name><name><surname>Yancey</surname><given-names>KB</given-names></name></person-group>. <article-title>Anti-basement membrane autoantibodies in patients with anti-epiligrin cicatricial pemphigoid bind the alpha subunit of laminin 5</article-title>. <source>J Invest Dermatol.</source> (<year>1995</year>) <volume>105</volume>:<fpage>543</fpage>&#x02013;<lpage>8</lpage>. <?supplied-pmid 7561156?><pub-id pub-id-type="pmid">7561156</pub-id></mixed-citation></ref><ref id="B132"><label>132.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Egan</surname><given-names>CA</given-names></name><name><surname>Lazarova</surname><given-names>Z</given-names></name><name><surname>Darling</surname><given-names>TN</given-names></name><name><surname>Yee</surname><given-names>C</given-names></name><name><surname>Cot&#x000e9;</surname><given-names>T</given-names></name><name><surname>Yancey</surname><given-names>KB</given-names></name></person-group>. <article-title>Anti-epiligrin cicatricial pemphigoid and relative risk for cancer</article-title>. <source>Lancet Lond Engl.</source> (<year>2001</year>) <volume>357</volume>:<fpage>1850</fpage>&#x02013;<lpage>1</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(00)04971-0</pub-id><?supplied-pmid 11410196?><pub-id pub-id-type="pmid">11410196</pub-id></mixed-citation></ref><ref id="B133"><label>133.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leverkus</surname><given-names>M</given-names></name><name><surname>Schmidt</surname><given-names>E</given-names></name><name><surname>Lazarova</surname><given-names>Z</given-names></name><name><surname>Br&#x000f6;cker</surname><given-names>EB</given-names></name><name><surname>Yancey</surname><given-names>KB</given-names></name><name><surname>Zillikens</surname><given-names>D</given-names></name></person-group>. <article-title>Antiepiligrin cicatricial pemphigoid: an underdiagnosed entity within the spectrum of scarring autoimmune subepidermal bullous diseases?</article-title>
<source>Arch Dermatol.</source> (<year>1999</year>) <volume>135</volume>:<fpage>1091</fpage>&#x02013;<lpage>8</lpage>. <?supplied-pmid 10490114?><pub-id pub-id-type="pmid">10490114</pub-id></mixed-citation></ref><ref id="B134"><label>134.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rashid</surname><given-names>KA</given-names></name><name><surname>G&#x000fc;rcan</surname><given-names>HM</given-names></name><name><surname>Ahmed</surname><given-names>AR</given-names></name></person-group>. <article-title>Antigen specificity in subsets of mucous membrane pemphigoid</article-title>. <source>J Invest Dermatol.</source> (<year>2006</year>) <volume>126</volume>:<fpage>2631</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1038/sj.jid.5700465</pub-id><?supplied-pmid 16810295?><pub-id pub-id-type="pmid">16810295</pub-id></mixed-citation></ref><ref id="B135"><label>135.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kasperkiewicz</surname><given-names>M</given-names></name><name><surname>Meier</surname><given-names>M</given-names></name><name><surname>Zillikens</surname><given-names>D</given-names></name><name><surname>Schmidt</surname><given-names>E</given-names></name></person-group>. <article-title>Linear IgA disease: successful application of immunoadsorption and review of the literature</article-title>. <source>Dermatology</source> (<year>2010</year>) <volume>220</volume>:<fpage>259</fpage>&#x02013;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1159/000279318</pub-id><?supplied-pmid 20130384?><pub-id pub-id-type="pmid">20130384</pub-id></mixed-citation></ref><ref id="B136"><label>136.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mintz</surname><given-names>EM</given-names></name><name><surname>Morel</surname><given-names>KD</given-names></name></person-group>. <article-title>Clinical features, diagnosis, and pathogenesis of chronic bullous disease of childhood</article-title>. <source>Dermatol Clin.</source> (<year>2011</year>) <volume>29</volume>:<fpage>459</fpage>&#x02013;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1016/j.det.2011.03.022</pub-id><?supplied-pmid 21605812?><pub-id pub-id-type="pmid">21605812</pub-id></mixed-citation></ref><ref id="B137"><label>137.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wojnarowska</surname><given-names>F</given-names></name><name><surname>Whitehead</surname><given-names>P</given-names></name><name><surname>Leigh</surname><given-names>IM</given-names></name><name><surname>Bhogal</surname><given-names>BS</given-names></name><name><surname>Black</surname><given-names>MM</given-names></name></person-group>. <article-title>Identification of the target antigen in chronic bullous disease of childhood and linear IgA disease of adults</article-title>. <source>Br J Dermatol.</source> (<year>1991</year>) <volume>124</volume>:<fpage>157</fpage>&#x02013;<lpage>62</lpage>. <?supplied-pmid 2003998?><pub-id pub-id-type="pmid">2003998</pub-id></mixed-citation></ref><ref id="B138"><label>138.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marinkovich</surname><given-names>MP</given-names></name><name><surname>Taylor</surname><given-names>TB</given-names></name><name><surname>Keene</surname><given-names>DR</given-names></name><name><surname>Burgeson</surname><given-names>RE</given-names></name><name><surname>Zone</surname><given-names>JJ</given-names></name></person-group>. <article-title>LAD-1, the linear IgA bullous dermatosis autoantigen, is a novel 120-kDa anchoring filament protein synthesized by epidermal cells</article-title>. <source>J Invest Dermatol.</source> (<year>1996</year>) <volume>106</volume>:<fpage>734</fpage>&#x02013;<lpage>8</lpage>. <?supplied-pmid 8618013?><pub-id pub-id-type="pmid">8618013</pub-id></mixed-citation></ref><ref id="B139"><label>139.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zone</surname><given-names>JJ</given-names></name><name><surname>Taylor</surname><given-names>TB</given-names></name><name><surname>Meyer</surname><given-names>LJ</given-names></name><name><surname>Petersen</surname><given-names>MJ</given-names></name></person-group>. <article-title>The 97 kDa linear IgA bullous disease antigen is identical to a portion of the extracellular domain of the 180 kDa bullous pemphigoid antigen, BPAg2</article-title>. <source>J Invest Dermatol.</source> (<year>1998</year>) <volume>110</volume>:<fpage>207</fpage>&#x02013;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1046/j.1523-1747.1998.00129.x</pub-id><?supplied-pmid 9506436?><pub-id pub-id-type="pmid">9506436</pub-id></mixed-citation></ref><ref id="B140"><label>140.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willsteed</surname><given-names>E</given-names></name><name><surname>Bhogal</surname><given-names>BS</given-names></name><name><surname>Black</surname><given-names>MM</given-names></name><name><surname>McKee</surname><given-names>P</given-names></name><name><surname>Wojnarowska</surname><given-names>F</given-names></name></person-group>. <article-title>Use of 1M NaCl split skin in the indirect immunofluorescence of the linear IgA bullous dermatoses</article-title>. <source>J Cutan Pathol.</source> (<year>1990</year>) <volume>17</volume>:<fpage>144</fpage>&#x02013;<lpage>8</lpage>. <?supplied-pmid 2197303?><pub-id pub-id-type="pmid">2197303</pub-id></mixed-citation></ref><ref id="B141"><label>141.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zillikens</surname><given-names>D</given-names></name><name><surname>Herzele</surname><given-names>K</given-names></name><name><surname>Georgi</surname><given-names>M</given-names></name><name><surname>Schmidt</surname><given-names>E</given-names></name><name><surname>Chimanovitch</surname><given-names>I</given-names></name><name><surname>Schumann</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Autoantibodies in a subgroup of patients with linear IgA disease react with the NC16A domain of BP1801</article-title>. <source>J Invest Dermatol.</source> (<year>1999</year>) <volume>113</volume>:<fpage>947</fpage>&#x02013;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1046/j.1523-1747.1999.00808.x</pub-id><?supplied-pmid 10594735?><pub-id pub-id-type="pmid">10594735</pub-id></mixed-citation></ref><ref id="B142"><label>142.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsuchisaka</surname><given-names>A</given-names></name><name><surname>Ohara</surname><given-names>K</given-names></name><name><surname>Ishii</surname><given-names>N</given-names></name><name><surname>Nguyen</surname><given-names>NT</given-names></name><name><surname>Marinkovich</surname><given-names>MP</given-names></name><name><surname>Hashimoto</surname><given-names>T</given-names></name></person-group>. <article-title>Type VII collagen is the major autoantigen for sublamina densa-type linear IgA bullous dermatosis</article-title>. <source>J Invest Dermatol.</source> (<year>2015</year>) <volume>135</volume>:<fpage>626</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1038/jid.2014.381</pub-id><?supplied-pmid 25207819?><pub-id pub-id-type="pmid">25207819</pub-id></mixed-citation></ref><ref id="B143"><label>143.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamagami</surname><given-names>J</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name><name><surname>Nagao</surname><given-names>K</given-names></name><name><surname>Funakoshi</surname><given-names>T</given-names></name><name><surname>Takahashi</surname><given-names>H</given-names></name><name><surname>Tanikawa</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Vancomycin mediates IgA autoreactivity in drug-induced linear iga bullous dermatosis</article-title>. <source>J Invest Dermatol.</source> (<year>2018</year>) <volume>138</volume>:<fpage>1473</fpage>&#x02013;<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1016/j.jid.2017.12.035</pub-id><?supplied-pmid 29410066?><pub-id pub-id-type="pmid">29410066</pub-id></mixed-citation></ref><ref id="B144"><label>144.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prost-Squarcioni</surname><given-names>C</given-names></name><name><surname>Caux</surname><given-names>F</given-names></name><name><surname>Schmidt</surname><given-names>E</given-names></name><name><surname>Jonkman</surname><given-names>MF</given-names></name><name><surname>Vassileva</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>SC</given-names></name><etal/></person-group>. <article-title>International bullous diseases group: consensus on diagnostic criteria for epidermolysis bullosa acquisita</article-title>. <source>Br J Dermatol.</source> (<year>2017</year>) <volume>179</volume>:<fpage>30</fpage>&#x02013;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1111/bjd.16138</pub-id><?supplied-pmid 29165796?><pub-id pub-id-type="pmid">29165796</pub-id></mixed-citation></ref><ref id="B145"><label>145.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zillikens</surname><given-names>D</given-names></name><name><surname>Kawahara</surname><given-names>Y</given-names></name><name><surname>Ishiko</surname><given-names>A</given-names></name><name><surname>Shimizu</surname><given-names>H</given-names></name><name><surname>Mayer</surname><given-names>J</given-names></name><name><surname>Rank</surname><given-names>CV</given-names></name><etal/></person-group>
<article-title>A novel subepidermal blistering disease with autoantibodies to a 200-kDa antigen of the basement membrane zone</article-title>. <source>J Invest Dermatol.</source> (<year>1996</year>) <volume>106</volume>:<fpage>1333</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">8752680</pub-id></mixed-citation></ref><ref id="B146"><label>146.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goletz</surname><given-names>S</given-names></name><name><surname>Hashimoto</surname><given-names>T</given-names></name><name><surname>Zillikens</surname><given-names>D</given-names></name><name><surname>Schmidt</surname><given-names>E</given-names></name></person-group>. <article-title>Anti-p200 pemphigoid</article-title>. <source>J Am Acad Dermatol.</source> (<year>2014</year>) <volume>71</volume>:<fpage>185</fpage>&#x02013;<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaad.2014.02.036</pub-id><?supplied-pmid 24767733?><pub-id pub-id-type="pmid">24767733</pub-id></mixed-citation></ref><ref id="B147"><label>147.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dainichi</surname><given-names>T</given-names></name><name><surname>Koga</surname><given-names>H</given-names></name><name><surname>Tsuji</surname><given-names>T</given-names></name><name><surname>Ishii</surname><given-names>N</given-names></name><name><surname>Ohyama</surname><given-names>B</given-names></name><name><surname>Ueda</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>From anti-p200 pemphigoid to anti-laminin gamma1 pemphigoid</article-title>. <source>J Dermatol.</source> (<year>2010</year>) <volume>37</volume>:<fpage>231</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1111/j.1346-8138.2009.00793.x</pub-id><?supplied-pmid 20507386?><pub-id pub-id-type="pmid">20507386</pub-id></mixed-citation></ref><ref id="B148"><label>148.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woodley</surname><given-names>DT</given-names></name><name><surname>Briggaman</surname><given-names>RA</given-names></name><name><surname>O'Keefe</surname><given-names>EJ</given-names></name><name><surname>Inman</surname><given-names>AO</given-names></name><name><surname>Queen</surname><given-names>LL</given-names></name><name><surname>Gammon</surname><given-names>WR</given-names></name></person-group>. <article-title>Identification of the skin basement-membrane autoantigen in epidermolysis bullosa acquisita</article-title>. <source>N Engl J Med.</source> (<year>1984</year>) <volume>310</volume>:<fpage>1007</fpage>&#x02013;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1056/NEJM198404193101602</pub-id><?supplied-pmid 6369131?><pub-id pub-id-type="pmid">6369131</pub-id></mixed-citation></ref><ref id="B149"><label>149.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vorobyev</surname><given-names>A</given-names></name><name><surname>Ludwig</surname><given-names>RJ</given-names></name><name><surname>Schmidt</surname><given-names>E</given-names></name></person-group>. <article-title>Clinical features and diagnosis of epidermolysis bullosa acquisita</article-title>. <source>Expert Rev Clin Immunol.</source> (<year>2017</year>) <volume>13</volume>:<fpage>157</fpage>&#x02013;<lpage>69</lpage>. <pub-id pub-id-type="doi">10.1080/1744666X.2016.1221343</pub-id><?supplied-pmid 27580464?><pub-id pub-id-type="pmid">27580464</pub-id></mixed-citation></ref><ref id="B150"><label>150.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ludwig</surname><given-names>RJ</given-names></name></person-group>. <article-title>Clinical presentation, pathogenesis, diagnosis, and treatment of epidermolysis bullosa acquisita</article-title>. <source>ISRN Dermatol.</source> (<year>2013</year>) <volume>2013</volume>:<fpage>812029</fpage>. <pub-id pub-id-type="doi">10.1155/2013/812029</pub-id><?supplied-pmid 23956869?><pub-id pub-id-type="pmid">23956869</pub-id></mixed-citation></ref><ref id="B151"><label>151.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roenigk</surname><given-names>HH</given-names></name><name><surname>Ryan</surname><given-names>JG</given-names></name><name><surname>Bergfeld</surname><given-names>WF</given-names></name></person-group>. <article-title>Epidermolysis bullosa acquisita</article-title>. Report of three cases and review of all published cases. <source>Arch Dermatol.</source> (<year>1971</year>) <volume>103</volume>:<fpage>1</fpage>&#x02013;<lpage>10</lpage>. <?supplied-pmid 4321800?><pub-id pub-id-type="pmid">4321800</pub-id></mixed-citation></ref><ref id="B152"><label>152.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buijsrogge</surname><given-names>JJA</given-names></name><name><surname>Diercks</surname><given-names>GFH</given-names></name><name><surname>Pas</surname><given-names>HH</given-names></name><name><surname>Jonkman</surname><given-names>MF</given-names></name></person-group>. <article-title>The many faces of epidermolysis bullosa acquisita after serration pattern analysis by direct immunofluorescence microscopy</article-title>. <source>Br J Dermatol.</source> (<year>2011</year>) <volume>165</volume>:<fpage>92</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2133.2011.10346.x</pub-id><?supplied-pmid 21457208?><pub-id pub-id-type="pmid">21457208</pub-id></mixed-citation></ref><ref id="B153"><label>153.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lapiere</surname><given-names>JC</given-names></name><name><surname>Woodley</surname><given-names>DT</given-names></name><name><surname>Parente</surname><given-names>MG</given-names></name><name><surname>Iwasaki</surname><given-names>T</given-names></name><name><surname>Wynn</surname><given-names>KC</given-names></name><name><surname>Christiano</surname><given-names>AM</given-names></name><etal/></person-group>. <article-title>Epitope mapping of type VII collagen</article-title>. Identification of discrete peptide sequences recognized by sera from patients with acquired epidermolysis bullosa. <source>J Clin Invest.</source> (<year>1993</year>) <volume>92</volume>:<fpage>1831</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1172/JCI116774</pub-id><?supplied-pmid 7691888?><pub-id pub-id-type="pmid">7691888</pub-id></mixed-citation></ref><ref id="B154"><label>154.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishii</surname><given-names>N</given-names></name><name><surname>Yoshida</surname><given-names>M</given-names></name><name><surname>Hisamatsu</surname><given-names>Y</given-names></name><name><surname>Ishida-Yamamoto</surname><given-names>A</given-names></name><name><surname>Nakane</surname><given-names>H</given-names></name><name><surname>Iizuka</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Epidermolysis bullosa acquisita sera react with distinct epitopes on the NC1 and NC2 domains of type VII collagen: study using immunoblotting of domain-specific recombinant proteins and postembedding immunoelectron microscopy</article-title>. <source>Br J Dermatol.</source> (<year>2004</year>) <volume>150</volume>:<fpage>843</fpage>&#x02013;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2133.2004.05933.x</pub-id><?supplied-pmid 15149495?><pub-id pub-id-type="pmid">15149495</pub-id></mixed-citation></ref><ref id="B155"><label>155.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>YH</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Noh</surname><given-names>EB</given-names></name><name><surname>Kim</surname><given-names>S-E</given-names></name><name><surname>Vorobyev</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Serum levels of anti-type VII collagen antibodies detected by enzyme-linked immunosorbent assay in patients with epidermolysis bullosa acquisita are correlated with the severity of skin lesions</article-title>. <source>J Eur Acad Dermatol Venereol.</source> (<year>2013</year>) <volume>27</volume>:<fpage>e224</fpage>&#x02013;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1111/j.1468-3083.2012.04617.x</pub-id><?supplied-pmid 22731917?><pub-id pub-id-type="pmid">22731917</pub-id></mixed-citation></ref><ref id="B156"><label>156.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>NH</given-names></name><name><surname>Bearn</surname><given-names>MA</given-names></name><name><surname>Herold</surname><given-names>J</given-names></name><name><surname>Ainsworth</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name></person-group>. <article-title>Blindness due to the IgA variant of epidermolysis bullosa acquisita, and treatment with osteo-odonto-keratoprosthesis</article-title>. <source>Br J Dermatol.</source> (<year>2007</year>) <volume>156</volume>:<fpage>775</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2133.2006.07739.x</pub-id><?supplied-pmid 17493079?><pub-id pub-id-type="pmid">17493079</pub-id></mixed-citation></ref><ref id="B157"><label>157.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vodegel</surname><given-names>RM</given-names></name><name><surname>de Jong</surname><given-names>MCJM</given-names></name><name><surname>Pas</surname><given-names>HH</given-names></name><name><surname>Jonkman</surname><given-names>MF</given-names></name></person-group>. <article-title>IgA-mediated epidermolysis bullosa acquisita: two cases and review of the literature</article-title>. <source>J Am Acad Dermatol.</source> (<year>2002</year>) <volume>47</volume>:<fpage>919</fpage>&#x02013;<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1067/mjd.2002.125079</pub-id><?supplied-pmid 12451379?><pub-id pub-id-type="pmid">12451379</pub-id></mixed-citation></ref><ref id="B158"><label>158.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonciolini</surname><given-names>V</given-names></name><name><surname>Bonciani</surname><given-names>D</given-names></name><name><surname>Verdelli</surname><given-names>A</given-names></name><name><surname>D'Errico</surname><given-names>A</given-names></name><name><surname>Antiga</surname><given-names>E</given-names></name><name><surname>Fabbri</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Newly described clinical and immunopathological feature of dermatitis herpetiformis</article-title>. <source>Clin Dev Immunol.</source> (<year>2012</year>) <volume>2012</volume>:<fpage>967974</fpage>. <pub-id pub-id-type="doi">10.1155/2012/967974</pub-id><?supplied-pmid 22701503?><pub-id pub-id-type="pmid">22701503</pub-id></mixed-citation></ref><ref id="B159"><label>159.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bolotin</surname><given-names>D</given-names></name><name><surname>Petronic-Rosic</surname><given-names>V</given-names></name></person-group>. <article-title>Dermatitis herpetiformis. Part I. epidemiology, pathogenesis, and clinical presentation</article-title>. <source>J Am Acad Dermatol.</source> (<year>2011</year>) <volume>64</volume>:<fpage>1017</fpage>&#x02013;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaad.2010.09.777</pub-id><?supplied-pmid 21571167?><pub-id pub-id-type="pmid">21571167</pub-id></mixed-citation></ref><ref id="B160"><label>160.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bolotin</surname><given-names>D</given-names></name><name><surname>Petronic-Rosic</surname><given-names>V</given-names></name></person-group>. <article-title>Dermatitis herpetiformis. Part II. diagnosis, management, and prognosis</article-title>. <source>J Am Acad Dermatol.</source> (<year>2011</year>) <volume>64</volume>:<fpage>1027</fpage>&#x02013;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaad.2010.09.776</pub-id><?supplied-pmid 21571168?><pub-id pub-id-type="pmid">21571168</pub-id></mixed-citation></ref><ref id="B161"><label>161.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>S&#x000e1;rdy</surname><given-names>M</given-names></name><name><surname>K&#x000e1;rp&#x000e1;ti</surname><given-names>S</given-names></name><name><surname>Merkl</surname><given-names>B</given-names></name><name><surname>Paulsson</surname><given-names>M</given-names></name><name><surname>Smyth</surname><given-names>N</given-names></name></person-group>. <article-title>Epidermal transglutaminase (TGase 3) is the autoantigen of dermatitis herpetiformis</article-title>. <source>J Exp Med.</source> (<year>2002</year>) <volume>195</volume>:<fpage>747</fpage>&#x02013;<lpage>757</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20011299</pub-id><?supplied-pmid 11901200?><pub-id pub-id-type="pmid">11901200</pub-id></mixed-citation></ref><ref id="B162"><label>162.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rose</surname><given-names>C</given-names></name><name><surname>Armbruster</surname><given-names>FP</given-names></name><name><surname>Ruppert</surname><given-names>J</given-names></name><name><surname>Igl</surname><given-names>B-W</given-names></name><name><surname>Zillikens</surname><given-names>D</given-names></name><name><surname>Shimanovich</surname><given-names>I</given-names></name></person-group>
<article-title>Autoantibodies against epidermal transglutaminase are a sensitive diagnostic marker in patients with dermatitis herpetiformis on a normal or gluten-free diet</article-title>. <source>J Am Acad Dermatol.</source> (<year>2009</year>) <volume>61</volume>:<fpage>39</fpage>&#x02013;<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaad.2008.12.037</pub-id><pub-id pub-id-type="pmid">19344979</pub-id></mixed-citation></ref></ref-list></back></article>